Expression of Bcl-2 and Ki-67 in Endometrial Lesions. by Nilavu, J
EXPRESSION OF Bcl-2 AND Ki-67 IN ENDOMETRIAL 
LESIONS 
 
 
 
 
 
 
Dissertation submitted in 
Partial fulfilment of the regulations required for the award of 
M.D. DEGREE 
In 
PATHOLOGY – BRANCH III 
 
 
 
 
 
 
THE   TAMILNADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
APRIL, 2013. 
  
 DECLARATION 
 
I hereby declare that the dissertation entitled EXPRESSION OF Bcl-2 
AND Ki-67 IN ENDOMETRIAL LESIONS was done by me in the 
Department of Pathology at Coimbatore medical college, Coimbatore 
during the period from August 2011 to July 2012 under the guidance and 
supervision of Dr. Arjunan M.D., Additional Professor, Department of 
Pathology, Coimbatore medical college, Coimbatore. This dissertation is 
submitted to the Tamilnadu Dr. M.G.R. Medical University, Chennai 
towards the partial fulfilment of the requirement for the award of M.D., 
Degree in Pathology. I have not submitted this dissertation on any 
previous occasion to any university for the award of any degree. 
 
 
Place:                                                                         
Date:                                                                          Dr. J. Nilavu. 
 
 
 
CERTIFICATE 
      This is to certify that dissertation entitled EXPRESSION OF Bcl-2 
AND Ki-67 IN ENDOMETRIAL LESIONS is a record of  bonafide 
work done by Dr. J. Nilavu, Post graduate student in the Department of 
Pathology, Coimbatore medical college and Hospital, Coimbatore, under 
the supervision of Dr. M. Murthy, M.D., Professor and Head,  
Department of pathology, Coimbatore medical college and Hospital, 
Coimbatore and under the guidance  of  Dr. Arjunan, M.D., Additional 
Professor, Department of Pathology, Coimbatore medical college and 
Hospital, Coimbatore, in partial fulfilment of the regulations of the 
Tamilnadu Dr. M.G.R. Medical University, Chennai towards the award of 
M.D. Degree(Branch III) in Pathology. 
                                                                                    
                                                                                  GUIDE 
                                                                              Dr.Arjunan,M.D., 
                                                                            Additional professor 
                                                                           Department of pathology                                                                                                      
Dr.R.VIMALA,M.D.,                                    Coimbatore medical college 
Dean, 
Coimbatore medical college. 
 
                                                               
Dr.M.Murthy,M.D.                                      
                                                                                 Professor and HOD 
                                                                            Department of Pathology,       
                                                                         Coimbatore medical college              
  
 
 
ACKNOWLEDGEMENT 
        There were many winds of change while sailing through the seasonal 
changes of research. Now it is time to acknowledge each and everyone 
who had provided moral support and motivation to complete my work.  
        First and foremost my heartfelt thanks to the dean Dr. Vimala M.D., 
for permitting me to undertake this study.  
        I am very grateful to Dr. M. Murthy M.D., Professor and Head, 
Department of pathology for his words of encouragement and hope 
throughout my period of study. 
        I deem with the great privilege to have worked under the guidance of          
Dr. Arjunan M.D., Additional Professor. I express my profound 
gratitude for his scholarly assistance.  
        I also express my special thanks to Dr. C. Lalitha M.D., Professor,    
and Associate professors, Dr. A. Dhanalakshmi M.D and                      
Dr. D. Kavitha M.D for helping me with research materials and input 
regarding my work.          
       I wish to place on records my heartfelt gratitude to all my teachers, 
colleagues and technical staffs for their constant support and 
encouragement throughout the course of the study. 
       I also wish to thank my parents and my dear husband who have 
rendered their help in many ways for the completion of this work. I 
specially thank my dear most child S.N.Sindhizhai who has in her own 
ways adjusted herself to the times I have been away and busy. 
       Above all I am truly thankful to the almighty for showering his 
abundant blessings on me always. 
Place: 
Date:                                                                      Dr. J. Nilavu 
 
 
 
 
 
 
 
 
 
 
  
 
Your digital receipt 
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt 
information 
regarding your submission. 
Paper ID 289156811 
Paper title EXPRESSION OF Bcl-2 AND Ki-67 IN ENDOMETRIAL LESIONS 
Assignment title Medical 
Author Nilavu 20101945 M.D. Pathology 
E-mail nilahere@gmail.com 
Submission time 17-Dec-2012 08:06PM 
Total words 14976 
First 100 words of your submission 
EXPRESSION OF Bcl-2 AND Ki-67 IN ENDOMETRIAL LESIONS Dissertation submitted in Partial 
fulfilment of the regulations required for the award of M.D. DEGREE In PATHOLOGY – BRANCH 
III  
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI APRIL, 2013. 
DECLARATION I 
hereby declare that the dissertation entitled EXPRESSION OF Bcl-2 AND Ki-67 IN ENDOMETRIAL 
LESIONS was done by me in the Department of Pathology at Coimbatore medical college, Coimbatore 
during the period from August 2011 to July 2012 under the guidance and supervision of Dr. Arjunan 
M.D., Additional Professor, Department of Pathology, Coimbatore medical college, Coimbatore. This 
dissertation is submitted to the Tamilnadu Dr. M.G.R.... 
Copyright 2012 Turnitin. All rights reserved. 
 
 
 
  
CONTENTS 
 
S.NO 
 
CONTENT PAGE 
NO 
1 INTRODUCTION 1 
2 AIM OF THE STUDY 2 
3 OBJECTIVE 3 
4 REVIEW OF LITERATURE 4 
5 MATERIALS AND METHODS 55 
6 RESULTS 61 
7 DISCUSSION 75 
8 CONCLUSION 84 
9 BIBLIOGRAPHY  
10 APPENDICES  
 ANNEXURE 1-PROFOMA  
 ANNEXURE 2- MASTER CHART  
 
 
 
 
LIST OF TABLES 
S.NO TITLE PAGE 
NO 
1. Distribution of cases. 
 
61 
2. Expression of Bcl-2 in various endometrial 
lesions 
62 
3. Expression of Ki67 in various endometrial 
lesions. 
64 
4. Comparison of Bcl-2 and Ki67 in various 
endometrial lesions. 
66 
5. Expression of Bcl-2 and Ki67 in cyclical 
endometrium. 
68 
6. Expression of Bcl-2 and Ki67 in disordered 
proliferative phase and hyperplasia. 
69 
7. Expression of Bcl-2 and Ki67 in EIN and 
Endometrial carcinoma. 
71 
 
8. Expression of Ki67 index in Endometrial 
carcinoma. 
73 
 
 
 
 
 
 
 
 
LIST OF CHARTS 
S.NO TITLE 
1. Distribution of cases. 
 
2. Expression of Bcl-2 in various endometrial lesions 
3. Expression of Ki67 in various endometrial lesions. 
4. Comparison of Bcl-2 and Ki67 in various 
endometrial lesions. 
5. Expression of Bcl-2 and Ki67 in cyclical 
endometrium. 
6. Expression of Bcl-2 and Ki67 in disordered 
proliferative phase and hyperplasia. 
7. Expression of Bcl-2 and Ki67 in EIN and 
Endometrial carcinoma. 
8. Expression of Ki67 index in Endometrial carcinoma. 
 
 
 
 
 
 
 
 
 
LIST OF COLOUR PLATES 
S.NO LIST OF COLOUR PLATES 
1,2,3 Bcl-2 expression in proliferative phase 
4 Ki-67 expression in proliferative phase 
5. H& E, Secretory phase 
6. Ki-67 expression in secretory phase 
7. H&E, simple hyperplasia 
8. Bcl-2 expression in simple hyperplasia 
9. Ki-67 expression in simple hyperplasia 
10. H&E, complex hyperplasia 
11. Ki-67 expression in complex hyperplasia 
12. H&E, EIN 
13. Bcl-2 expression in EIN 
14. Ki-67 expression in EIN 
15. Gross picture of  endometrial carcinoma 
16. H&E, endometrial adenocarcinoma grade-1 
17. Bcl-2 expression in endometrial adenocarcinoma 
grade-1 
18. H&E, endometrial adenocarcinoma grade-2 
19. Bcl-2 expression in endometrial adenocarcinoma 
grade-2 
20. H&E, endometrial adenocarcinoma grade-3 
21. Ki-67 expression in endometrial adenocarcinoma  
grade-3 
22,23 Serous adenocarcinoma H&E 
24. Serous adenocarcinoma Ki-67 
25.  Serous intra epithelial carcinoma. 
ABBREVIATION 
 
Bcl- B cell lymphoma. 
EIN- Endometrial intraepithelial neoplasia. 
TNF- Tumour necrosis factor 
FADD- Fas associated death domain 
DUB- Dysfunctional uterine bleeding. 
HRT- Hormone replacement therapy 
PAS- Periodic acid Schiff 
IHC- Immunohistochemistry 
MMMT- Malignant mesodermal ( mullerian) mixed tumour. 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
             The human endometrium shows dynamic morphological changes 
during the menstrual cycle in reproductive women. These cyclical  
changes  include cell proliferation  with   high  mitotic  activity,  secretory  
changes  and  shedding  of  endometrial  cells  regulated  by  ovarian  sex  
steroids.  There should be some inhibitory mechanism to counterbalance 
such proliferation to maintain tissue homeostasis. Thus apoptosis which is  
programmed  cell  death  is  critical  in  regulation  of  the  menstrual  
cycle.  
              There should be a balance between the apoptotic and mitotic 
activity for the regulation of normal menstrual cycle. The  aim  of  this  
thesis is to study the apoptotic  and  mitotic  activity  in  the endometrium  
of  various  lesions  which  includes cyclical  endometrium ,  endometrial  
hyperplasias, premalignant conditions and malignancy. This is  
determined  immunohistochemically  by  using  markers  such  as  Bcl-2  
and  Ki-67.  
                     Bcl-2  is  an  anti-apoptotic  gene  involved  in  the  
regulation  of  apoptosis  and  Ki-67 is  a  recognized  indicator  of  cell  
mitotic  activity.  Increased expression of both indicates tumorigenesis.  
Thus  the  pattern of  expression  in  hyperplastic  and  premalignant  
states  of endometrium  helps  us  to  study  the  progression  of  these  
conditions  to  frank  malignancy.     
AIM OF THE STUDY 
 
       The aim of this study is to study the apoptotic and mitotic activity in 
endometrium, the balance of which is essential for the regulation of 
normal endometrial development during the menstrual cycle. This is 
studied immunohistochemically by using markers such as Bcl-2 an anti-
apoptotic gene involved in the regulation of apoptosis and Ki-67 a 
recognized indicator of cell mitotic activity in endometrial lesions such as 
cyclical endometrium, endometrial hyperplasia, premalignant conditions 
and malignancy. 
  
OBJECTIVE 
 
1. To determine the expression of Bcl-2 and Ki-67 in cyclical 
endometrium in the proliferative and secretory phases. 
2. To study the expression of Bcl-2 and Ki-67 in hyperplastic states 
and premalignant conditions such as EIN. 
3. To determine the pattern of expression of Bcl-2 and Ki-67 in 
endometrial carcinoma. 
  
REVIEW OF LITERATURE 
APOPTOSIS 
         The term apoptosis was coined by Kerr and Williams in 1972 who 
defined the process of cell death
1
. Apoptosis is a programmed cell death 
in which the cells die by activating enzymes that cause degradation of the 
cells nuclear DNA and cytoplasmic proteins
2
. The aim of the apoptosis is 
to eliminate the aged, unwanted and potentially harmful cells during the 
development and adulthood. It occurs in physiological conditions such as 
involution of hormone dependant tissues upon hormone withdrawal such 
as breakdown of endometrium during menstrual cycle, ovarian follicles 
undergoing atresia in menopause, the regression of lactating breast after 
weaning and pathological condition such as in neoplasm. 
APOPTOSIS IN ENDOMETRIUM 
        The human endometrium consists of three phases of the cycle such 
as proliferative phase and secretory phase followed by menstrual phase. 
The follicular phase is  characterized by rapid cell proliferation, which is 
predominently controlled by ovarian  estrogens but also by other growth 
factors such as epidermal growth factor, fibroblastic growth factor, 
angiogenic growth factor etc. In the luteal phase, progesterone influences 
the secretory differentiation of the endometrium where the apoptosis 
begins and levels increase with the forth coming menstruation. 
PROCESS OF APOPTOSIS 
        The process of apoptosis may be divided into two phases such as 
initiation phase and execution phase. Apoptosis is initiated by two 
distinct pathways such as  
                      1. Intrinsic or mitochondrial pathway. 
                      2. Extrinsic or death receptor initiated pathway. 
MITOCHONDRIAL PATHWAY 
       Mitochondrial pathway is the major mechanism of apoptosis. 
Mitochondria contains protein such as cytochrome-c that is essential for 
life, if released into the cytoplasm, they activate caspases which initiates 
apoptosis. This release of mitochondrial proteins is controlled by a finely 
orchestrated balance between pro and anti - apoptotic members of Bcl 
family.  
THE BCL-2 PROTEIN  
       Caenorhabditis elegans, a nematode possess two genes ced-3 and 
ced-4, responsible for the programmed cell death, during the worm 
development and another gene ced-9 prevents their action. Bcl-2 (B cell 
lymphoma)  gene  was  identified in human when  it  caused  t(14:18)  in  
most  cases  of  follicular  lymphoma,  which  promoted  the  survival  of  
cytokine  dependant  hematopoietic  cell  in  the  absence  of  cytokine 
3
.  
Later    Bcl-2 was found to have structure and function homologous to the 
ced-9 gene of the nematode and thus emerged as an anti-apoptotic gene. 
There are more  than  20  members  of  the  Bcl  family , and  most  
of  them  function  to  regulate  apoptosis.  Certain proteins of this family 
are involved in anti-apoptotic mechanism the main ones being Bcl-2,   
Bcl-x, and Mcl-1. The pro apoptotic proteins are Bax, Bak and Bid. Thus 
anti apoptotic and pro apoptotic protein groups form homodimers and 
heterodimers between each other and resulting effect depends on the 
dominance of one of them. Bcl-2 is the best studied protein which acts as 
an antioxidant in the cell, protects cytochrome-c from being released 
from mitochondria and participates in the regulation of caspase proteins. 
Bcl-2 is situated in the outer membrane of the mitochondria and 
endoplasmic reticulum of the cytoplasm. It is also present in the nuclear 
envelope. Thus Bcl-2 controls the mitochondrial permeability and 
prevents leakage of  mitochondrial proteins that have the ability to trigger 
cell death. 
When cells are debilitated of survival signals or their DNA is 
damaged, or when misfolded proteins induce stress of endoplasmic 
reticulum, the sensors of damage or stress are activated. These sensors are 
also members of the Bcl family, and they include proteins called Bim, 
Bid, and Bad that contain a single “Bcl -2 homology domain” and are 
called “BH-3 only proteins”. The sensors in turn activate two critical pro 
apoptotic effectors, Bax and Bak, which forms oligomers that insert into 
the mitochondrial membranes and create channels that allow proteins 
from the inner mitochondrial membrane to leak out in to the cytoplasm. 
BH-3 only proteins may also bind to and block the function of Bcl-2 and 
Bcl-x. At the same time Bcl-2 and Bcl-x synthesis may decline.  
The net result of Bax-Bak activation coupled with loss of the 
protective functions of the anti-apoptotic Bcl family members is the 
release into the cytoplasm several mitochondrial proteins of which 
cytochrome–c, a protein involved in mitochondrial respiration binds to a 
protein known as Apaf-1(apoptosis activating factor-1). This complex 
binds caspase-9, the critical initiator of the mitochondrial pathway, and 
the enzyme cleaves the adjacent caspase molecules thus setting up auto 
amplification process. 
EXTRINSIC PATHWAY 
           Extrinsic pathway is initiated by the involvement of the plasma 
membrane death receptor, the best one being type-1 TNF receptor. The 
cytoplasmic portion of this receptor contains a domain called death 
domain. Attached to this death domain is a related protein called 
Fas(CD95). The ligand for Fas is called the Fas ligand which is expressed 
on the T cells that recognize self antigens.  When FasL binds to Fas, more 
than three molecules are brought together and their cytoplasmic death 
domains form a binding site for the adapter protein called FADD(Fas- 
associated death domain), which in turn binds to caspase-8 in its inactive 
form. This complex combines with many caspase-8 molecules to generate 
active caspase, which initiates a series of caspase activation thus mediates 
the execution phase of apoptosis. 
MORPHOLOGICAL CHANGES IN APOPTOSIS 
         Morphological changes taking place during apoptosis are cell 
shrinkage, condensation of chromatin, formation of cytoplasmic blebs 
followed by formation of apoptotic bodies. These apoptotic bodies are 
then phagocytosed by the macrophages which are then degraded by the 
lysosomal enzymes. 
APOPTOTIC BODIES 
           On tissue sections apoptotic bodies appear as round or ovoid 
bodies with densely eosinophilic cytoplasm and fragments of chromatin. 
Because of the rapidity of the process of apoptosis such as cell shrinkage 
and phagocytosis, they are difficult to find in the histological sections. 
Further unlike necrosis it is not accompanied by inflammation. This also 
makes apoptosis difficult to be detected. 
      Thus the cyclical endometrial activity consisting of proliferation and 
menstrual shedding with increased apoptotic and mitotic activity has lead 
in the recent past years, immunohistochemical study of Bcl-2 in 
endometrium. 
                   Ki-67 – THE NUCLEAR ANTIGEN
8
 
 
        The proliferative activity of a cell is determined by Ki-67 antigen. 
This monoclonal antibody was derived by immunizing mice with 
Hodgkins lymphoma cells. This is named after the city of origin, Kiel 
which is located in Germany. Ki-67 is predominantly present in the 
nuclear matrix and is expressed in all active phases of the cell cycle such 
as G1, S, G2 and M phase.  It is absent in the G0 phase of the cell cycle, 
which are in the resting phase, and undetectable during the DNA repair 
process. It is particularly detected in the nucleus during the interphase 
stage of the cell division. Ki67 is involved in the regulation and 
maintenance of cell division. Expression of this nuclear antigen by a cell 
denotes that particular cell is the active phase of the cell cycle. MIB-1 is 
the antibody against different epitope of the similar proliferating antigen.              
UTERINE CYCLE
4
 
         The mucosal lining of the uterus is composed of the glands and the   
stroma. The endometrium of the corpus is composed of two layer i.e 
stratum functionalis and stratum basalis. Stratum basalis is adjacent to 
myometrium and consists of tubular glands and compact stroma. There is 
no secretory or mitotic activity in these glands.  Stratum functionalis is 
futher divided in to superficial stratum compactum and the deep stratum 
spongiosum. Stratum spongiosum has maximal secretory activity   and 
unresponsive stroma where as stratum compactum  responds  remarkably  
to  hormonal  stimulation  with  a  prominent predecidual reaction  and  
numerous  granulocytes,  where  as  the  glands  are  stretched  thin  with  
less secretory activity.
  
                  
Junction between the endometrium and the endocervical 
epithelium constitutes the isthmic endometrium. The isthmic 
endometrium consists of the glands with features between those of the 
endometrium proper and the endocervix. The glands are typically 
flattened and slit-like lined by an epithelium containing a mixture of 
undistinguished columnar cells admixed with ciliated cells. The stroma is 
more fibrous and displaying cells that are more spindled. 
Normal menstrual cycle 
       Normal  menstrual  cycle  is  defined  as  bleeding  from  a  secretory   
endometrium – associated  with  an  ovulatory  cycle- not  exceeding  a  
length  of  5 days.
22
  The  menstrual  cycle  in  the  uterus  is  divided  in  
to  two  main  phases. 
 
1. Proliferative phase 
2. Secretory phase.    
1. The normal proliferative phase
5
 
        This phase generally lasts two weeks but under physiological 
conditions, may fluctuate between ten and twenty days.   
         In the early part of this phase the endometrium is thin with sparse, 
small, straight glands and a loose stroma of spindle cells. At 8-10 days, 
the endometrial thickness increases, mainly as a result of stromal edema 
which peaks at day ten. In the preovulatory period as the estrogen levels 
starts decreasing, the stromal edema comes down which is overtaken by 
the continuous growth of the glands which becomes slightly tortuous. 
          Glandular epithelium is lined by tall columnar cells with basophilic 
cytoplasm and the nuclei are arranged in pseudostratified appearance 
staggered at varying heights, most in the basal half. The nuclei are ovoid 
with coarse chromatin. The endometrial stroma is densely cellular, 
consisting of cells that are small and oval with indistinct cytoplasm and 
hyperchromatic nuclei. Mitosis is frequent.  
         In the late proliferative phase the glands show increased tortuosity 
and variability in size. Mitosis becomes less numerous in the late 
proliferative phase. Subnuclear vacuoles and stromal edema starts to 
appear.  
The secretory phase
4,6
 
         Ovulation as defined occurs on day 14 of the cycle. In first and 
second day of post ovulatory day, the endometrial glands appear slightly 
larger and less basophilic because of the interruption of the 
pseudostratified epithelium by vacuoles.   
Early secretory phase 
          The appearance of the subnuclear vacuoles heralds the onset of 
early secretory phase which last from day fifteen to nineteen. The basal 
vacuoles push the nuclei to the middle of the cell giving a piano key like 
appearance. At seventeenth day there are uniform subnuclear vacuolation 
and no mitosis. Eighteenth day the vacuoles are moved toward the lumen 
accompanied by supranuclear discharge. Nineteenth day the nuclei again 
migrates back to the base. Mitotic activity is typically not present. 
Mid secretory phase 
         The mid secretory phase last from day nineteen to twenty five. This 
is a phase of secretory exhaustion. At day twenty there is a peak 
intraluminal secretion. Day twenty one is characterized by an increase in 
stromal edema with prominent spiral arterioles.  Day twenty two is 
characterised by a peak in stromal edema. By day twenty three the edema 
regresses and the stromal changes commence predecidualisation. By day 
twenty four predecidua extends to bridge vascular elements. By day 
twenty five edema is progressively reabsorbed and glands in this phase 
are irregular and mitosis ceases to be apparent. Apoptotic bodies 
normally appear in the glandular epithelium in response to progesterone’s 
down regulation of the proto-oncogene Bcl-2.
4
 
Late secretory phase 
        Late secretory phase is from day twenty six to twenty eight. It shows 
extension of predecidual change from the surface lining downward 
deeply into the stratum compactum. By day twenty seven numerous 
granulated lymphocytes appear. In the central spongy part of the 
endometrium the glands have a characteristic saw tooth appearance. 
Menstrual phase
7 
        If pregnancy has not occurred, the late secretory phase leads 
inevitably to menstrual phase, starts 14 days after ovulation. This phase is 
recognized histologically by crumbling of the stroma and glandular 
collapse and hemorrhage in the superficial stroma. The stromal cells 
aggregate in to tightly clustered ball and separate from the glands, which 
have an unusually deep blue colour, and overlying epithelial cells appear 
degenerative. Also there is presence of plump epithelial glandular cells 
displaying secretory exhaustion. These tissue fragments are separated by 
red blood cells and neutrophils. 
IMMUNOHISTOCHEMISTRY OF NORMAL ENDOMETRIUM
8
 
• The endometrial glands and stroma are both positive for estrogen 
and progesterone receptors.  
•  Endometrial glands stain positive for Bcl-2, which is expressed 
high in the proliferative phase and decreased in the secretory phase.  
• Endometrial glands are positive for cytokeratin 7 and negative for 
cytokeratin 20. 
• Endometrial stroma is positive for CD10 and Bcl-2 and negative 
for CD34, in contrast to the cervical stroma.  
• Stromal cells are positive for smooth mucle actin and negative for 
desmin.  
• Granulated lymphocytes show positivity for CD56. 
  Many studies have been conducted using Bcl-2 and Ki-67 in 
normal cyclical endometrium. Reviews of these studies are as follows. 
       Mertens H J MM
9
 et al states that Bcl-2 showed increased expression 
in the proliferative phase and diminished significantly in the secretory 
phase, especially in the glandular epithelial cells. Ki-67 also showed the 
same cyclical pattern with a later onset.  
       T. E. Vaskivuo
10
 et al states that Bcl-2 showed increased expression 
in the proliferative phase and very low expression in the secretory phase. 
Ki-67 was detected predominantly in the proliferative phase.  
       X J Tao
11
 et al states that Bcl-2 immunoreactivity was maximal 
during the proliferative phase and decreased in the secretory phase.  
      A. Gompel
12
 et al states that Bcl-2 expression was high in the 
glandular cells and peaked at the proliferative phase. Bcl-2 expression 
disappeared with the onset of secretory phase.  
      Pavel Havelka
13
 et al states that increased expression of Bcl-2 protein 
was observed in artificial cycles in the surface epithelium and in the 
glands of the compact layer, as well  as in the spongious layer.  
      R. Konno
14
 et al states that the cyclic changes of survivin and Bcl-2 
showed inverse relationship with Bcl-2 expression being maximum in the 
proliferative phase whereas survivin showed increased expression in the 
secretory phase. 
       Lydia J. Taylor
15
 et al states that marked increase in the expression of 
Bcl-2 in the glandular epithelium and the stroma of the polyps in the 
proliferative phase in comparison with the  proliferative endometrium and 
decreased in secretory phase polyps. 
        Hugo Maia
16
 states that in endometrial polyps Ki-67, p53 and Bcl-2 
expression was detected frequently during the proliferative phase than 
those in secretory phase of the cycle.  
        Rebacca K. Jones
17
 et al states that rise in the stromal Bcl-2 
expression is due to the up regulation of Bcl-2 expression by endometrial 
granular lymphocytes in the late secretory, premenstrual and early 
pregnancy endometrium. Ki-67 were high in the proliferative phase and 
early secretory phase and fell in the late secretory phase. 
POST MENOPAUSAL ENDOMETRIUM
4
 
         After the cessation of estrogen and progesterone by the ovary, the 
endometrium is no longer stimulated and thus undergoes atrophy. The 
post menopausal endometrium is usually thin and inactive, although there 
is some variation in thickness.The glands are typically small and scant 
often unevenly distributed throughout the tissue. The glands are lined by 
cuboidal or flattened cells. The stroma becomes fibrous and the stromal 
cells lose their cytoplasm and appear cellular. Exposure to low levels of 
exogenous or endogenous estrogen, can result in a mildly expanded 
endometrium. 
            Another pattern of post menopausal endometrium is the cystic 
atrophy. This type of endometrium consists of cystically dilated glands, 
lined by flattened epithelium and the lumen contains partly non-specific 
secretion and partly transudate. This change may be so marked and may 
be visible grossly also called swiss cheese endometrium. The cystic 
atrophy arises as a result of benign hyperplasia present at the time of 
menopause which regresses with withdrawal of hormonal support or 
simple obstruction of the gland ostia as a result of stromal fibrosis. 
DYSFUNCTIONAL UTERINE BLEEDING
 
        According to Ackerman, bleeding not associated with an organic 
cause in women of child bearing age belongs to the large and somewhat 
nebulous category known as dysfunctional uterine bleeding. The changes 
in the endometrium that confirm the patient has abnormal bleeding are 
the presence of fibrin clumps in the endometrial stroma, a finding usually 
not seen in the normal menstrual endometrium, the identification of 
fragmented pieces with dense stromal cellularity- a process known as 
stromal crumbling and the presence of increased number of apoptotic 
bodies at the base of the glands so called Bernirschke granules
22
. 
 He classified DUB as ovulatory and anovulatory. 
Ovulatory type is again classified as 
1. Inadequate proliferative phase  
2. Inadequate secretory phase 
3. Irregular shedding of the endometrium 
An anovulatory cycle results in prolonged unremitting estrogen 
stimulation which results in hyperplasia. All gradations of this 
phenomenon occur from disordered proliferative endometrium to an 
atypical one that approaches the appearance of adenocarcinoma
66
. Davey 
D.A
67
 defined DUB as an abnormal bleeding from the uterus in the 
absence of organic disease of the genital tract. Author classified DUB 
into primary and secondary. 
Primary DUB- Primarily there is dysfunction in the pituitary, 
hypothalamus, ovary or uterus. 
Secondary DUB - Factors such as IUCD insertion, hormonal 
contraception or secondary to systemic diseases such as endocrinopathies.  
Primary DUB is classified as Ovulatory DUB and anovulatory DUB 
Ovulatory DUB includes 
 1. Corpus luteal insufficiency 
 2.  Persistent corpus luteum. 
Anovulatory DUB includes  
1. Insufficient follicular development   
2. Persistent ovarian follicle                                                                                               
 
 
 
Classification of possible endocrine abnormalities associated endometrial 
histology and typical bleeding patterns in DUB 
Type Cycle Endometrial 
histology 
Type of bleeding 
ovulatory 1. Short cycle- short 
proliferative phase. (ovarian 
hypersensitivity) 
2.Long cycle- Long 
proliferative phase.(slow 
follicle development) 
Normal 
endometrium 
 
 
Normal 
endometrium 
Menorrhagia. 
Polymenorrhoea,  
 
 
Menorrhagia. 
Oligomenorrhoea,  
 Luteal 
insufficiency 
1. Insufficiency – short luteal 
phase. 
 
 
 
2.Persistent (Halban’s disease) 
 
 
 
Irregular ripening 
of endometrium or 
deficient secretory 
endometrium 
 
Irregular shedding 
of endometrium 
Menorrhagia, 
Premenstrual 
spotting,  
 
 
Prolonged 
menstruation. 
Anovulatory  1. Insufficient follicles short 
cycle(low estrogen level) 
 
 
2.Persistent follicle or 
polycystic ovaries(high level 
of estrogen ) 
 
 
Inadequate 
proliferative or 
atrophic 
endometrium 
 
Proliferative  or 
hyperplastic 
endometrium 
Polymenorrhoea, 
menorrhagia. 
 
 
 
Metropathica 
haemorrhagica, 
Oligomenorrhoea, 
 
 
 
DISORDERED PROLIFERATIVE ENDOMETRIUM
4,6,18,19
  
        Prolonged proliferation of endometrium as a result of anovulation 
gives rise to disordered proliferative endometrium. It is an intermediate 
between normal proliferative and benign hyperplastic endometrium. The 
patient usually presents with irregular uterine bleeding. It is characterised 
by cystically dilated endometrial gland distributed irregularly with 
stromal breakdown which is patchy, resulting from focal fibrin thrombus. 
Tubal metaplasia of endometrial glands is also common.  
       Rekha M D
20
 et al states that there was a good correlation of the Bcl-
2 expression and the apoptotic cell morphology in the different categories 
of the endometrium of dysfunctional uterine bleeding such as 
anovulatory, simple hyperplasia and secretory phase etc.  
       Zhou LL
21
 states that the Bcl-2 protein expression changes 
periodically in normal cycle. The Bcl-2 expression intensity is enhanced 
in hyperplastic endometrium. 
ENDOMETRIAL EPITHELIAL METAPLASIA
4,6 
        Endometrial metaplasia is change in cellular differentiation of one 
type of epithelium, to another type that is not present in the normal 
endometrium. The most common forms of endometrial metaplasia are 
those in which the endometrial glands assume a morphology along the 
mullerian differentiation such as serous, mucinous , or squamous. 
Metaplasia occurs in the benign endometrium, EIN and endometrial 
carcinomas. 
SQUAMOUS METAPLASIA 
        Squamous metaplasia occurs in benign reactive process and 
carcinoma. The causes associated with benign changes are chronic 
endometritis, intrauterine devices, and trauma. There are two types of 
squamous metaplasia, such as  
• Typical squamous metaplasia. 
• Morular metaplasia. 
        Typical squamous metaplasia occurs as scattered surface foci. When 
whole of the endometrium is extensively replaced by squamous 
epithelium the condition is called ichthyosis uteri. This condition is 
associated with cervical obstruction and chronic inflammation. 
         Morular metaplasia occurs in the form cohesive, small, round and              
‘ granuloma-like’ aggregates of squamous cells located in the glands or 
between the glands. The morules may enlarge into sheets with multiple 
glands arranged radially around the periphery. It can be associated with 
central necrosis. Sometimes morular metaplasia is associated with some 
degree of glandular crowding, where EIN has to be ruled out. The 
transition of morular metaplasia to EIN is made by glandular crowding 
and altered cytological features within the glandular epithelium, as 
compared to the normal endometrium in other areas. 
MUCINOUS METAPLASIA 
         Mucinous metaplasia is characterized by endometrial glands lined 
by cuboidal or columnar epithelium with prominent intracytoplasmic 
mucin , along with isolated pockets of extracellular mucin droplets. 
Goblets are seen occasionally. The presence of endometrial stroma 
around these mucinous glands differentiates from endocervical 
contamination in biopsy specimens. There are three types of mucinous 
metaplasia as follows 
• Type A is characterised by glands lined by endocervical- like 
cuboidal epithelium, which is most commonly present in 
perimenopausal women. 
• Type B metaplasia show architectural complexity and 
pseudopapillary pattern. 
• Type C consisted of mucinous epithelium of glands arranged in 
cribriform pattern or exhibiting microglandular or villoglandular 
architecture. This pattern is associated with significant risk of 
adenocarcinoma. 
 CILIATED (TUBAL) METAPLASIA 
         The tubal metaplasia is characterised by the columnar epithelium 
lined by cilia, with clear round cells seen between the cells similar to the 
tubal epithelium and eosinophilic luminal borders. Normally ciliated 
epithelial cells are found in the proliferative phase and are associated with 
estrogen stimulation. 
 CLEAR CELL METAPLASIA 
        Clear cell metaplasia is characterized by epithelial cells with 
abundant clear cytoplasm. It is very rare and can occur in pregnancy. It 
should be distinguished from clear cell carcinoma by the following 
features.  
FEATURES FAVOURING CLEAR CELL METAPLASIA OVER 
CLEAR CELL CARCINOMA. 
• Normal architecture and distribution of the endometrial glands. 
• Bland nuclear features. 
• Metaplasia is usually present focally. 
• There is no visible tumour made out grossly. 
•  Stromal invasion is not seen. 
• Estrogen receptor is strongly positive. 
HOBNAIL METAPLASIA 
        Hobnail metaplasia is rare and is caused by, degenerative changes 
associated with necrosis and exfoliation artefact. It is also closely 
associated with arias stella reaction. This metaplasia is characterised by 
glandular cells consisting of rounded nuclear protrusion beyond the 
cytoplasmic borders. 
EOSINOPHILIC METAPLASIA 
        Eosinophilic or oxyphilic metaplasia is characterized by glands lined 
by cells with abundant granular eosinophilic cytoplasm. The abundant 
granular cytoplasm is due to the increased mitochondria. 
        Endometrial mesenchymal metaplasia includes cartilaginous and 
osseous metaplasia, smooth muscle metaplasia, glial metaplasia, and 
extramedullary hematopoiesis. 
ENDOMETRIAL POLYPS 
        Endometrial polyps are biphasic growth of endometrial glands and 
stroma which protrude into the uterine cavity. It is one of the most 
common causes of abnormal uterine bleeding. Polyps arise as a result of 
monoclonal overgrowth of genetically altered stromal cells. Polyps are 
associated with hyperestrogenism. Their incidence is increased with HRT 
usage and tamoxifen therapy. 
        Microscopically polyp shows abnormally dilated glands with 
glandular crowding lined by atrophic epithelium or lined by poorly 
developed secretory or proliferative epithelium. The glands are set in a 
fibrous stroma. In some areas, the stroma shows marked hyalinisation. 
Characteristically the stroma contains thick walled blood vessels and 
sometimes thin ectatic vessels. Morphologically polyps are divided in to 
three types as follows. 
• Proliferative or hyperplastic polyps consisting of proliferative, 
crowded glands. 
• Atrophic polyps consisting of atrophic glands. 
• Functional polyp consisting of glands resembling surrounding 
cyclical endometrium. 
ENDOMETRIAL HYPERPLASIA 
DEFINITION
8 
        Endometrial hyperplasia is defined as increase in gland to stromal 
ratio, where there is estrogen induced proliferation of glands that are 
irregular in shape and size.  
          Endometrial hyperplasia is the morphological consequence of 
either,  
1. Persistent follicle with high levels of estrogen for a long period , 
2. Repeated anovulatory cycles. 
3. Excess of estrogen as a result of peripheral conversion of androgen 
as in polycystic ovarian syndrome. 
4. Estrogen secreting ovarian neoplasm. 
Patients with endometrial hyperplasia most frequently present with 
abnormal vaginal bleeding. Grossly hyperplastic endometrium is often 
characterised by abundant white to tan tissue that may have a diffuse or 
polypoid distribution and protrude in to the endometrial cavity. There are 
various classification of endometrial hyperplasia 
Tavassoli and Krauss (1978)
68
 classified as  
Cystic hyperplasia 
Adenomatous hyperplasia 
Atypical hyperplasia. 
 Ronnett B.M and Robert J. Kurman(2004)
8  
classifies endometrial 
hyperplasia as1. Hyperplasia without cytologic atypia( non atypical 
hyperplasia) 
     a) Simple  
     b)Complex 
 
2. Hyperplasia with cytologic atypia( atypical hyperplasia) 
     a) Simple 
     b)Complex 
Simple or complex types based on the degree of glandular crowding. 
WHO
18
 classification of endometrial hyperplasia depending upon both 
cytologic and architectural abnormalities (2003)  
Hyperplasia without atypia 
     a) Simple hyperplasia without atypia 
     b) Complex hyperplasia without atypia 
Atypical hyperplasias 
     a) Simple atypical hyperplasia 
    b) Complex atypical hyperplasia 
HYPERPLASIAS
2,8,18,19
 
       Simple hyperplasia without atypia is characterized by slight 
increase in gland to stromal ratio. The glands exhibit marked variation in 
size and shape such as round and tubular glands to tortuous and cystically 
dilated glands (so called cystic or swiss cheese hyperplasia). The 
epithelial growth pattern and cytology are similar to that of proliferative 
endometrium. The epithelial cells lining the glands are stratified and have 
oval nuclei with evenly dispersed chromatin and inconspicuous nucleoli. 
The stromal cellularity is increased as seen in proliferative phase. The 
blood vessels are dilated and are frequently thrombosed. Mitotic figures 
and apoptotic bodies are frequently noted. Approximately 1% of these 
lesions progress to adenocarcinoma. 
        Complex hyperplasia without atypia is characterized by increased 
gland crowding in comparison to simple hyperplasia. There is glandular 
enlargement and budding. The glands develop numerous branching 
channels and papillary infoldings. Cell stratification and polarity are 
generally maintained and the cells are cytologically normal. Mitotic 
activity is less than 5 mitosis per 10 high power field. Apoptotic bodies 
are frequently seen. About 3% of these lesions progress to 
adenocarcinoma. 
Atypical hyperplasia 
Cytological atypia is characterized by the presence of increased nuclear to 
cytoplasmic ratio and loss of polarity, with the nuclei being large and 
round. Nuclear pleomorphism, anisonucleosis and nuclear 
hyperchromasia is also seen. Nucleus is characterized by uneven 
distribution of the chromatin and prominent large nucleoli. Apoptotic 
bodies and mitosis are frequently seen. 
       Simple hyperplasia with atypia is a rare type of hyperplasia which 
has similar architectural features of simple hyperplasia, but is associated 
with cytologic atypia.  About 8% of these lesions progress to carcinoma.                               
Complex hyperplasia with atypia has architectural features similar to 
that of complex hyperplasia with epithelial cells showing cytological 
atypia. About 25% of these lesions progress to carcinoma. 
      Robert.J.Kurman
8
 et al states that in general observations Bcl-2 
expression is increased in simple hyperplasia, but decreased in atypical 
hyperplasias and invasive endometrial carcinomas
25,27,31,74-79
.  
       Morsi, Hassan
23
 et el states that Bcl-2 and Ki-67 show increased 
expression in proliferative endometrium, post menopausal endometrium 
and complex hyperplasia.  Secretory endometrium showed decreased 
expression of both the markers. In endometrial carcinoma Ki-67 showed 
increased expression as the grade progressed, where as Bcl-2 reacted 
only weakly and only in grade 1 cancer.  
        Robert
24
 et al states that, the Ki-67 mean index of 68 endometrial 
samples in descending order of frequency were as follows. Highest 
expression was observed in proliferative phase followed by complex 
hyperplasia, atypical complex hyperplasia, and simple hyperplasia. The 
least score was observed in atrophic endometrium. 
        Theodore H. Niemann
25
 et al states that Bcl-2 protein expression 
was 100% in complex hyperplasia, 25% in complex atypical hyperplasia 
and 34% in cases of carcinoma. Complex atypical hyperplasia and 
carcinoma showed focal staining which was less in intensity than the 
normal proliferative endometrium. 
        Risberg .B
26
 states that Bcl-2 showed highest expression in the 
proliferative phase, polyps and hyperplasias. Bcl-2 expression was 
decreased in secretory phases and carcinomas. Ki-67 expression was 
highest in carcinomas, proliferative phases than hyperplasia. 
       Olga B Ioffe
27
 et al states that cytoplasmic Bcl-2 expression 
increased from proliferative endometrium to simple hyperplasia and 
decreased in complex hyperplasia and carcinomas. Ki-67 index was 
increased in proliferative endometrium and carcinoma and was decreased 
in simple and complex hyperplasia. 
        LBMora
28
 states that Ki-67 index was higher in endometrial 
adenocarcinoma than in hyperplasia.  Bcl-2 expression was lower in 
endometrial adenocarcinoma than hyperplasia and was higher in 
proliferative phase. 
       Altaner S
29
 et al states that there was no statistically significant 
difference of Bcl-2 expression between the polyps, simple hyperplasia, 
complex hyperplasia and endometrial adenocarcinoma. Positive Ki-67 
was highest in endometrial adenocarcinoma followed by endometrial 
hyperplasia. 
ENDOMETRIAL INTRAEPITHELIAL NEOPLASM
4,6.18
 
         Endometrial intraepithelial neoplasia is a clonal proliferation of 
architecturally and cytologically altered premalignant endometrial glands. 
Malignant transformation to endometrioid (type-I) endometrial 
adenocarcinoma is at a rate of 26 to 37%. The following factors are 
involved in the development of EIN such as  
• Genetic mutations such as inactivation of PTEN a tumour 
suppressor gene is the most common genetic alteration found to 
occur in cancer preceded by EIN. 
•  PAX 2 inactivation and microsatellite instability. 
• Activating mutations of the KRAS2 cellular oncogene. 
• Other factors are unopposed estrogen, obesity, tamoxifen therapy 
etc.  
EIN DIAGNOSTIC CRITERIA 
1. Architecture- The gland area exceeds the stromal area. EIN lesions 
consist of aggregates of tubular glands or slightly branching glands, in 
which the surface area of the glands exceeds that of the stroma. The 
crowded appearance of the glands are readily visualised under low 
magnificantion. These EIN glands have an epicentre with maximum 
glands concentrated in the periphery. The stroma in between the glands is 
hormone dependant which ranges from stroma of functionalis to more 
fibrous non cycling stroma of the basalis or polyps. The size of the glands 
and the distance between them determine the amount of stroma which is 
expressed as volume percentage stroma. In EIN the volume percentage 
stroma should be less than 55%. To evaluate this, ocular grids with 50- 
100 regularly placed points indicated by intersecting lines are used. 
Recently computerised histomorphometry is used to calculate the volume 
percentage stroma. 
2. Cytology – The cytology of architectually crowded area is different 
from that of the background endometrial glands, where the crowded 
glands show round non-stratified nuclei or elongated pseudostratifed 
nuclei, with clumped or granular chromatin, with change in nucleoli. The 
cytoplasm may be of endometrioid differentiation or of non endometrioid 
differentiation such as tubal, mucinous, secretory or eosinophilic 
epithelium. 
3.Size- An EIN lesion should be greater than 1mm in maximum 
dimension that usually  encompasses >5-6 glands. 
 
4. Exclusion of benign mimics - Features of EIN overlap with benign 
conditions which must be carefully discriminated from EIN itself. 
• Endometrial polyps with irregularly placed glands and variable 
cytology are misinterpreted as EIN. But polyps usually exhibit 
altered stroma, thick vessels and randomly placed irregular glands. 
• Benign endometrial hyperplasia should not be confused with EIN. 
Benign hyperplasia changes usually involve the entire endometrial 
compartment, and have an irregular random pattern of 
architectural and cytological alteration. 
5. Exclusion of carcinoma- EIN are composed of clusters of individual 
glands with simple lining epithelium, whereas adenocarcinoma shows 
one or more patterns such as solid, cribriform, or complex interlacing 
maze like growth. These architectural changes of endometrial cancer 
reflect loss of basement contact between the epithelial cells. 
          Mahrosa M.M.Khedr
30
 et al states that normal proliferative 
endometrium expressed high levels of both Ki-67 and Bcl-2. Ki-67 
positivity sequentially increased from endometrial hyperplasia through 
EIN to endometrial carcinoma. In contrast Bcl-2 positivity was decreased 
significantly in cases of endometrial carcinoma mainly the high grade. 
 
 ENDOMETRIAL ADENOCARCINOMA
4,6,18,22
 
          Carcinoma of the endometrium is increasing in frequency 
compared with the carcinoma of the cervix. Endometrial cancers usually 
arises in postmenopausal women and 80% presents with postmenopausal 
bleeding. The peak incidence is in the 55 to 65 year old age group. 
Endometrial adenocarcinoma is broadly classified into two types, 
endometrioid  (type I) estrogen dependant tumours and non-endometrioid 
(type II) adenocarcinoma less related to estrogen stimulation. The two 
main types of endometrial carcinoma exhibit different molecular 
alterations, consistent with the dualistic model of tumorigenesis
38
 which 
is explained below. 
TYPES OF ENDOMETRIAL ADENOCARCINOMA   
Endometrioid type I estrogen dependant endometrial 
adenocarcinoma 
           Endometrioid tumours account for the majority of sporadic 
endometrial carcinomas (70-80%). In relation to the estrogen dependency 
these occur in younger, pre menopausal women. These tumours have low 
propensity for lymphatic spread and myometrial invasion than the non 
endometrioid adenocarcinoma. They are positive for estrogen and 
progesterone receptors and generally carry a good prognosis. These 
tumours exhibit molecular alterations such as microsatellite instability, 
inactivated PTEN tumour suppressor gene, K- ras mutations, and 
abnormalities in b-catenin gene associated with b-catenin nuclear 
accumulation. 
39
    
Non- endometrioid type II estrogen independant endometrial 
carcinoma. 
            This type of tumour occurs in post menopausal women and 
account for 10-20% of endometrial carcinoma. They are not associated 
with the clinical evidence of estrogen stimulation and typically arise from 
atrophic endometrium, frequently in the setting of poorly differentiated 
phenotype of carcinosarcoma or undifferentiated carcinoma. They have 
rapid courses, a high degree of nuclear pleomorphism, frequent aneuploid 
DNA content, deeper myometrial invasion, increased lymphatic spread, 
low sensitivity to progestin and a poor prognosis. In contrast to estrogen 
dependant tumors these show loss of heterozygosity at different loci, 
altered p53, and abnormalities in genes regulating mitotic check points
40
 
RISK FACTORS 
Estrogens  
         Both exogenous and endogenous estrogen plays an important role in 
the development of endometrial hyperplasia and carcinoma. From 
numerous case control studies it is evident that the threat of carcinoma in 
women taking unopposed estrogens is elevated 3 to 6 fold
28,29
, rising to 
9.5 fold if unopposed  estrogens has been used for 10 years or longer
41
. 
Endogenous estrogen as in later menopause and low parity are the factors 
related to over all life time estrogen exposure. 
Tamoxifen 
       Tamoxifen is a drug used in the chemotherapy of breast cancer. Its 
administration is associated with a slightly increased (two or three times) 
risk of endometrial adenocarcinoma.
42
 
Polycystic ovary syndrome 
        Polycystic ovarian syndrome is a constellation of endocrine disorder 
sharing features of  anovulation or infrequent ovulation , androgen excess 
and polycystic ovaries
43
.The  patients are usually infertile , have elevated 
estrogen levels, and associated insulin resistance may cause type 2 
diabetes
44
. Endometrial carcinoma occurs in less than 5% of those women 
with polycystic ovaries .
45
 
Obesity 
        Numerous studies firmly link obesity as a highly significant risk 
factor in women developing endometrial cancer,
46,47
. Adipose tissue is the 
major site of aromatisation of androgen to estrogen and thus associated 
with increased risk of cancer. 
Diabetes  
        3- 17% of the women with endometrial carcinoma has diabetes 
while 17-64% have an abnormal glucose tolerance test. 
Ovarian lesions 
         Ovarian lesions are associated with prolonged excessive and 
unopposed estrogen production that sometimes causes benign 
endometrial hyperplasia, EIN, and endometrioid adenocarcinoma that is 
almost always low grade and early stage. The most common lesions 
include granulosa cell tumor, thecoma, polycystic ovary disease, and 
hyperthecosis. Diffuse ovarian hyperthecosis is characterized by the 
presence of luteinized cells dispersed singly or in aggregates throughout 
the hyperplastic stroma. 
Sex cord stromal tumor 
          The incidence of endometrial carcinoma in patients with granulosa 
cell tumor is about 9-13%.  Granulosa cell tumors are associated with 
endometrial hyperplasia and these patients presents with post menopausal 
bleeding. 
 
Reproductive factors 
         Nulliparity is strongly associated with endometrial carcinoma in the 
pre menopausal age group. Infertility caused by anovulation and 
progesterone insufficiency is also associated with increased risk of 
endometrial carcinoma. Many studies have proved that even early 
menarche and late menopause are also associated with endometrial 
carcinoma. 
CLASSIFICATION OF ENDOMETRIAL 
ADENOCARCINOMA
1
(8) 
ENDOMETRIOD ADENOCARCINOMA 
Villoglandular  
Secretory 
Ciliated cell 
Endometriod adenocarcinoma with squamous differentiation 
CLEAR CELL ADENOCARCINOMA 
SEROUS ADENOCARCINOMA 
SQUAMOUS CARCINOMA 
MUCINOUS ADENOCARCINOMA 
MIXED TYPE OF CARCINOMA 
UNDIFFERENTIATED CARCINOMA   
                                                          
1
 Modified WHO and International Society of Gynecological pathologist  
Histologic classification of endometrial carcinoma 
GROSS FEATURES 
            The uterus may be slightly or grossly enlarged but it may be of 
normal size or even small and atrophic particularly in postmenopausal 
women. Most arise in the corpus and present either as a single mass or, 
two or three separate masses, or diffuse thickening of the endometrium. 
Carcinomas are frequently situated in the posterior wall. The most 
common appearance is that of a raised, rough perhaps papillary area of 
the endometrium with a shaggy surface and ulceration, frequently 
occupying at least half of the surface area of the endometrium. 
Sometimes the tumour is polypoid with a narrow base. 
MICROSCOPIC FEATURES 
                The glandular pattern and cellular features generally resembles 
that of the proliferative endometrium showing a complicated architecture 
which includes solid growth, maze like interconnected lumen, 
villoglandular appearance or cribriform growth. Multilayered epithelial 
cells are nearly always seen. Solid growth may vary widely in extent 
which is an important feature in tumour grading. The individual epithelial 
cells are large, exhibiting nuclear stratification, coarsely clumped 
chromatin and prominent nucleoli. Individual tumours are associated with 
focal differentiation to squamous, mucinous, or tubal epithelium. Some 
endometrioid adenocarcinoma secretes abundant extracellular mucin, but 
lack intracellular mucin which differentiates it from mucinous 
adenocarcinoma. Mitotic figures are less in well differentiated tumours. 
Endometrial adenocarcinoma spread centrifugally in to the stroma. 
Foamy histiocytes are commonly seen in stroma of carcinoma 
endometrium. But the association between the foam cells and tumour 
grade is not yet proved. Myoinvasion is common and diagnosed only 
when the malignant glands have transgressed the endometrial myometrial 
junction in to the underlying muscular uterine wall.  
International Federation of Gynaecology and Obstetrics (FIGO) 
recommended by WHO . 
ARCHITECTURE GRADING 
Grade 1 -  5% or less of non- squamous solid growth. 
Grade 2-   6-50% of non-squamous solid growth. 
Grade3-    more than 50% of non – squamous growth. 
CYTOLOGICAL GRADING
8 
Grade1- nuclei are oval, mildly enlarged, and have evenly dispersed 
chromatin. 
Grade2- features intermediate to grades 1 and 3. 
 
Grade3- nuclei are markedly enlarged and pleomorphic, with irregular 
coarse chromatin , and prominent eosinophilic nucleoli. 
Note: Cytological features used in formulating the final grade 
1. High degree of nuclear atypia not correlating with the architectural 
grade raises the grade1 or grade2 tumours by one level. 
2. In carcinomas such as serous adenocarcinoma, clear cell 
adenocarcinomas and areas of squamous differentiation nuclear grade 
takes primacy over the architecture. 
Low grade endometrioid carcinoma 
       The low grade endometrioid carcinoma consists of less than 5% of 
solid growth. These tumours are characterized by malignant glands lined 
by columnar cells similar to that of the normal proliferative endometrium, 
where the nucleus are arranged uniformly maintaining the polarity. But 
the glands are more irregular and larger than benign endometrium.  Many 
of the variants comes under this category which includes, villoglandular 
variant, endometrioid adenocarcinoma with squamous differentiation, 
secretory variant,  those showing mucinous differentiation and tubal 
differentiation . 
 
 
Intermediate grade endometrioid carcinoma 
        These tumours are categorised as endometrial adenocarcinoma 
which has solid growth that constitute 5-50% of the tumour. The 
cytological grade is characterized by high degree of nuclear 
pleomorphism than grade-1 tumours, which includes, three to four times 
variation in the nuclear size and even more coarsely clumped chromatin. 
High grade endometrioid adenocarcinoma 
        High grade endometrioid adenocarcinoma is characterized by the 
presence of solid growth greater than 50%. Some degree of solid growth 
pattern with higher nuclear grade pushes the grade to grade-3. Non-
endometrioid tumours such as serous carcinomas, neuroendocrine 
carcinoma and undifferentiated carcinomas come under grade-3. 
VARIANTS OF ENDOMETRIAL CARCINOMA(8) 
Endometrial adenocarcinoma with squamous differentiation 
        Squamous differentiation ranges from keratinised epithelium that 
exfoliates anucleate squames to morules, which are cells with indistinct 
cytoplasmic borders arranged in sheets. Depending on the degree of 
differentiation of squamous cells, the term adenoacanthoma was used for 
the tumors with well differentiated squamous component and adeno 
squamous carcinoma for poorly differentiated squamous component. 
Endometrial carcinoma without squamous differentiation and 
adenoacanthoma carry better prognosis than adenosquamous carcinoma.  
Criteria for identifying squamous differentiation in endometrioid 
adenocarcinoma 
Squamous differentiation  is suggested by the presence of any one of the 
following
50
 
• Keratin or keratin pearls demonstrated without special stain 
• Intercellular bridges 
• At least three of the following: 
- Sheet-like growth without gland formation  
- Distinct cell margins 
- Deeply eosinophilic or glassy cytoplasm 
- A lower nuclear cytoplasmic ratio than the surrounding tumour. 
Endometrial adenocarcinoma with secretory differentiation 
        Secretory adenocarcinoma is a rare variant of endometriod 
adenocarcinoma consisting of glands resembling those of early or mid 
secretory endometrium
51
. The most common changes are subnuclear and 
supranuclear  vacuolation.  Secretary adenocarcinoma are associated with  
good prognosis
50
. 
 
Endometrial adenocarcinoma with ciliary cell differentiation  
          Ciliated cell carcinoma is rare
50,52
. Ciliated cells are uncommon in 
adenocarcinoma but occasionally individual ciliated cells can be found. 
More rarely, extensive ciliated cell is present throughout. A minimum of 
75% of the cells should be ciliated to call it as ciliated cell carcinoma. 
Endometrioid carcinomas with ciliated cell differentiation have a good 
prognosis. 
Endometrial adenocarcinoma villoglandular variant 
          This variant consists of slender, long, delicate papillae in well- 
differentiated neoplasm that may be predominantly of typical 
endometrioid type or entirely papillary
53
. This tumour is similar to 
villoglandular adenocarcinoma arising in the endocervix, where it occurs 
in the younger women and often associated with good prognosis. 
Psammoma bodies are rarely encountered
54
. The cytological features are 
that of a grade-1 carcinoma. Because these tumours are well 
differentiated they usually have a favorable outcome
55
. 
MUCINOUS ADENOCARCINOMA 
         Mucinous adenocarcinoma comprises 1-9% of all endometrial 
adenocarcinomas
31,32
. Mucinous endometrial adenocarcinomas usually 
arise in conjunction with an endometrioid component and thus can be 
considered within the endometrioid class of endometrial 
adenocarcinoma
4
. 
      A higher frequency of mucinous adenocarcinoma is observed in 
patients receiving tamoxifen and synthetic progesterone
33,34
. Grossly it is 
similar to endometrioid adenocarcinoma, apart from the infrequent 
prominence of the secreted tenacious mucus. Microscopically mucinous 
adenocarcinoma of the endometrium resembles mucinous tumour found 
in the endocervix. While many endometrioid carcinoma contain focal 
mucin, the mucinous component in mucinous adenocarcinoma should 
involve atleast half the cells
35
. The involved cells are tall with basal 
nuclei and prominent intracytoplasmic mucin. Mucicarmine, periodic 
acid schiff (PAS) and alcian blue are all useful to amplify the staining. 
         Most tumors are well differentiated (grade-1) but grade-2 and 
grade-3 tumours are occasionally described
31
. Poorly differentiated 
tumours lose their ability to produce mucin. Lymph node metastases may 
be well differentiated. In some cases exophytic complex filiform papillary 
fragments of mucinous endometrial adenocarcinoma are encountered in 
biopsy specimens.  An extremely bland cytology, rare mitosis and a 
tendency to break apart, make these tumors difficult to recognize , as they 
resemble endocervical epithelium. The abundance of mucinous 
epithelium, delicate supportive stroma, and alternating mucinous and 
non- mucinous differentiation often coexisting with a microglandular    
component are typical
36,37
. 
        The behaviour of mucinous adenocarcinoma is that of endometrioid 
carcinomas. As most are well differentiated the prognosis is generally 
favorable. 
SEROUS ENDOMETRIAL INTRA EPITHELIAL CARCINOMA 
         Endometrial intra epithelial carcinoma is the precursor of serous 
adenocarcinoma of the endometrium
56,40
. It typically occurs in post 
menopausal women in a background of atrophic endometrium. There is 
abrupt transition of this atrophic endometrium where the endometrial 
surface glands, are replaced by highly pleomorphic cells with marked 
nuclear atypia and mitotic activity, without invading the stroma. The cells 
express increased Ki67 index and a strong p53 immunoreactivity and loss 
of estrogen and progesterone receptors
40
. 
SEROUS ADENOCARCINOMA 
        Serous adenocarcinoma is an aggressive form of endometrial cancer 
accounting for 1-10% of all endometrial cancer. The patients are 
generally about 4-10 years older than women with endometrioid 
carcinomas, rarely have received estrogen therapy and lack previous or 
concurrent EIN or hyperplasia
57. 
Most women are parous( 90%). Few are 
obese (10%) or have diabetes
58
. Typically they have normal serum 
estrogen levels 
59
. Gross features are similar to endometrioid carcinomas, 
although many appear as bulky and necrotic masses
40
. 
         Histologically they typically have branching papillae, lined by 
highly pleomorphic cells. The cells lining the papillae exhibit nuclear 
stratification, which forms tufts that can detach freely. The glandular 
structures are irregularly shaped and often lined by polygonal rather than 
columnar cells
60
. The nuclei are large, exhibiting high degree of nuclear 
pleomorphism and atypia containing macronucleoli. Mitosis figures are 
increased in number. There is considerable increase in the apotosis and 
numerous apoptotic bodies are seen. Atypical mitotic figures and tumour 
giant cells are common. 
         Psammoma bodies are encountered in one- third of the cases
61
. 
Myometrial invasion
62
 is very common and it elicits granulation tissue 
type of response in the invasion site. The molecular changes of p53 
mutation is seen in 80-90% of the serous carcinoma which on  IHC shows 
diffuse and intense nuclear staining involving almost all tumor cells
63,40
. 
Ki67 immunohistochemistry shows a high labeling index(about 40%) in 
serous carcinoma and  estrogen and progesterone receptors are absent or 
only weakly expressed in most tumors
64
. PTEN gene is intact and 
expressed in normal levels in most serous carcinomas
65
. 
CLEAR CELL ADENOCARCINOMA 
        Clear cell adenocarcinoma is also a prototype of type II endometrial 
carcinoma. It comprises about 1-6% of all endometrial carcinomas and 
occur at an older age (mean age 65-69years) than endometrioid 
adenocarcinoma 
50.
. The women generally are less often obese, less often 
have often have diabetes mellitus, and less frequently have taken 
hormone replacement therapy. 
         These tumours are characterised by a variety of patterns, including 
papillary, tubulocystic and solid. Papillary pattern is the most common. 
The papillae are often small and rounded and frequently show hyalinised 
fibrovascular cores. The tumour cells exhibit prominent clear cytoplasm 
due to abundant glycogen or may display oxyphilic cytoplasm. Typical 
hobnail cells which frequently line papillae and tubules are characterized 
by a nucleus that bulges in to the lumen.  Cells lining the cyst are 
commonly flattened are cuboidal. Intracytoplasmic hyaline bodies are 
very frequent and characteristic of this tumour. Mucin may be seen in the 
lumens of the tubules and cyst. However eosinophilic hyaline mucin 
droplets are seen as intracytoplasmic vacuoles – targetoid cells are a 
characteristic feature. The nuclei are pleomorphic with prominent 
nucleoli and mitotic figures are frequent. Rarely psammoma bodies may 
be found. In contrast to serous adenocarcinomas these are p53 negative. 
MIXED ADENOCARCINOMA 
       Mixed adenocarcinomas consists of mixture of type-I endometriod  
adenocarcinomas or their variants (including mucinous adenocarcinoma), 
and type-II non- endometrioid carcinomas. The minor component should 
constitute at least 10% of the neoplasm. The prognosis depends on the 
most aggressive component
60
.  
MALIGNANT MESODERMAL(MULLERIAN) MIXED 
TUMOUR(CARCINOSARCOMA) 
        Malignant mesodermal mixed tumours constitute less than 5% of 
malignant tumors of the uterine corpus. The risk factors associated with 
MMMT are body weight, exogenous estrogen, nulliparity, tamoxifen 
therapy, and pelvic irradiation for various carcinomas. Grossly the 
tumour appears necrotic, fleshy, hemorrhagic polypoidal mass filling the 
uterine cavity. Extensive myometrial involvement is seen even grossly. 
Microscopically it shows biphasic pattern of the growth and high grade 
nuclear features. Epithelial component may present as any special type 
such as mucinous, clear cell, endometrioid, squamous and 
undifferentiated carcinoma. The stromal component can be homologous 
such as fibrosarcoma, stromal sarcoma and leiomyosarcoma or it can be 
heterologous consisting of liposarcoma, rhabdomyosarcoma, 
osteosarcoma and chondrosarcoma. This tumor carries worst prognosis. 
UNDIFFERENTIATED CARCINOMA 
          Carcinomas that lack any evidence of differentiation after extensive 
sampling are classified as undifferentiated carcinoma. They constitute 
less than 2% of endometrial tumors
35,,
. They are composed of large 
pleomorphic cells with prominent nuclear atypia. This is classified 
separately in to large cell and small cell type even though there is no 
difference in survival. The prognosis is poor. Other types of endometrial 
carcinoma are squamous cell carcinoma, transitional cell carcinoma, 
small cell carcinoma etc 
Staging of endometrial carcinoma- International federation of 
Gynecologists and Obstetricians, 1988 
Stage I- Tumour confined to the uterus 
   Ia: Tumour confined to the endometrium. 
       Ib: Tumour invades < 50% of the myometrial wall 
       Ic: Tumour invades > 50% of the myometrial wall 
Stage II- Tumour extends in to the uterine cervix  
       IIa- Tumour extends into the endocervical epithelial surface or    
glands. 
       IIb- Tumour infiltrates the cervical stroma. 
 
 
Stage III- Tumour extends outside the uterus 
       IIIa- Tumour involves serosa and /or adnexa, and/or positive ascitis,           
or/peritoneal  washings. 
       IIIb- Direct extension or metastasis to the vagina. 
       IIIc- Pelvic and / or para-aortic lymph node metastases. 
Stage IV-  
       IVa- Tumour invades bladder mucosa and /or bowel mucosa. 
       IVb- Distant metastases( excluding metastases to vagina, pelvic 
serosa or adnexa)  
MYOMETRIAL INVASION 
      Invasive adenocarcinoma infiltrates the myometrium in the form of 
jagged, irregular branching glands which is surrounded by inflammed 
granulation tissue. Invasive glands exhibit microcystic, elongated and 
fragmented pattern within the myometrium. Involvement of adenomyosis 
by carcinoma should be distinguished from myoinvasion because the 
former does not imply worse prognosis than carcinoma limited to the 
endometrium. It is distinguished by the following features. 
• Neoplastic glands in the adenomyosis usually have a blunt advancing 
front where as infiltrating carcinomas has a jagged infiltrating edge. 
• Foci of adenomyosis are surrounded by hyperplastic myometrium a 
feature not present in myoinvasion. 
• CD10  positive endometrial stromal cells distinguishes carcinoma 
involving adenomyosis from myoinvasion. 
PROGNOSTIC FACTORS 
1. Stage of the disease 
2. Histological type 
3. Histological grade 
4. Myometrial invasion  
5. Cervical involvement 
6. Adnexal involvement 
7. Lymphovascular involvement. 
8. Positive peritoneal cytology 
Other prognostic factors are DNA ploidy, diploidy is associated with 
higher disease free survival . Immunohistochemical staining for ER, Bcl-
2, c-erbB2, p53 and Ki-67 has been suggested as important parameters in 
assessing prognosis in endometrial carcinoma
18
. Finally, a number of 
molecular alterations have also been proposed as putative prognostic 
factors for endometrial carcinoma including assessment of microsatellite 
instability and alterations in PTEN and B- catenin.  
 Poorly differentiated carcinomas, clear cell and serous carcinomas shows 
increased apoptotic bodies and thus increased apoptotic index in contrast 
to well differentiated endometriod carcinoma. Hence there is decreased 
Bcl-2 expression in these tumors.  This decreased Bcl-2 expression is 
associated with various other prognostic factors such as PR negative 
status, increasing depth of invasion, and increasing FIGO    stage 
,72
. Two 
other studies correlated the loss of Bcl-2 protein to recurrence of the 
tumour and lymph node metastases.
 
In a study which included 115 
samples of endometrial adenocarcinoma, Ki-67 index was correlated with 
the cell type, FIGO stage and histological subtype. Thus it can be taken as 
a independant prognostic factor. 
       Yamauchi
66 
et al states that expression of Bcl-2 progressively 
decreased from low grade to high grade carcinoma and Ki67 index 
increased from low grade to high grade carcinoma.  
       Kosmas
67
 et al states that Ki67 immunocytochemistry showed type-II 
endometrioid adenocarcinoma showed higher expression than type-I 
carcinoma. High grade tumours showed increased Ki67 expression than 
low grade tumours. Ki67 index was higher in proliferative phase 
endometrium than that of grade1 and type-I endometrioid 
adenocarcinoma. In secretory phase the expression was markedly 
diminished. 
Helga B. Salvesan
68
 et al states that apart from age, mean vessel 
density, FIGO stage, p53 and Ki67 protein expression are independant 
prognostic factors. 
 Bozdogen
69
 et al states that Bcl-2 expression was maximum in 
hyperplasia compared to carcinoma. In normal endometrium Bcl-2 
staining showed increased intensity in the proliferative phase, but 
decreased in the early and mid secretory phase and reappeared in the late 
secretory phase. 
          Dahmoun M
70 
et al states that Bcl-2 showed no correlation to 
apoptotic index. The Ki67 index was higher and more heterogenous in 
grade 2-3 tumours than grade1 tumour.  
         Halperin R
71
 et al states that the endometriod grade1 to grade 2 
cases were characteried by increased immunoreactivity for Bcl-2, where 
as serous papillary endometrial adenocarcinoma and poorly differentiated 
adenocarcinoma showed immunonegativity for Bcl2.  
         Wenxin Zheng 
72
 et al states that Bcl-2 staining intensity was higher 
in the proliferative endometrium and hyperplasia, which diminished in  
endometrioid adenocarcinoma and serous papillary adenocarcinoma. 
  
MATERIALS AND METHODS 
This study is done on endometrial specimens received by the department 
of pathology, Coimbatore Medical college during the period August 
2011-July 2012. 
INCLUSION CRITERIA 
All endometrial biopsy and hysterectomy specimens received by the 
department of pathology. 
EXCLUSION CRITERIA 
1. Specimen not received in formalin. 
2. Inadequate specimen. 
METHODOLOGY 
Sections are cut at 4 microns in thickness and hematoxylin and eosin 
staining was done. For immunohistochemistry sections of 4 microns 
thickness are cut and taken on coated slides, which are coated with 
gelatin –chrome alum mixture and kept in incubation at 58 degrees 
overnight. These unstained slides are used for running 
immunohistochemistry by a two step indirect technique. 
 
 
PROCEDURE OF IMMUNOHISTOCHEMSITRY 
METHOD: Two step indirect technique. 
PRINCIPLES OF THE PROCEDURE: 
Antigens  in  tissues  and  cells  are  detected  by  a  two-stage process:  
the  binding  of the  primary antibody to specific epitopes and the 
subsequent detection of this binding by a colorimetric reaction. Tissue 
sections are taken on coated glass slides, which are coated with gelatin – 
chrome alum mixture. The sections are then incubated overnight at 37 
degree Celsius for dewaxing .Antigen retrieval is done by the microwave 
heating of tissue sections in buffer solution. The buffer used is tris EDTA 
and citrate buffer. In my study both Bcl-2 and Ki67 antigens are retrived 
by heating in tris EDTA buffer which has a pH of 9. The tissue sections 
are then treated with Peroxide-Block for blocking the endogenous 
peroxidise activity. Power block is to prevent the protein- protein 
interaction and reduce excessive background staining. 
REAGENTS USED 
1) Peroxide Block: 3%hydrogen peroxide in water. 
2) Power Block Reagent: A highly effective universal protein blocking 
reagent. Contains casein and propriety additives in PBS with 15Mm 
sodium azide. 
3) Chromogen: DAB-3,3’-diaminobenzidine. 
4) Liquid DAB Substrate: Comprises Tris buffer containing the peroxide 
and stabilizers. 
5) SuperEnhancer Reagent. 
6) Pol-HRP Reagent. 
7) Counter stain: Mayer’s Hematoxylin. 
8) Buffer solutions:  
TRIS BUFFER: (ph -7.6) 
TRIS Buffer salt : 0.605 gm 
Sodium chloride : 8 gm 
Distilled water : 1000 ml 
1N Hydrochloric acid : 3 ml 
CITRATE BUFFER: (ph-6.0) 
Trisodium citrate : 2.94 gm 
Distilled water : 1000 ml 
1 N Hydrochloric acid : 5 ml 
TRIS EDTA: (ph-9.0) 
TRIS Buffer salt : 6.05 gm 
Disodium EDTA : 0.744 gm 
Distilled water : 1000 ml                      
PROCEDURE: 
1) Deparaffinise the sections in xylene for 30 minutes. 
2) Wash in absolute alcohol for 5 minutes with 2 changes. 
3) Wash the slides in tap water for 10 minutes. 
4) Rinse in distilled water for 5 minutes. 
5) Antigen retrieval is done by placing the slides with  tris EDTA buffer  
solution in microwave : Medium-10 minutes: High-10 minutes. 
6) Cool to room temperature and rinsed in distilled  water. 
7) Wash in TBS buffer for 5 minutes with 2 changes. 
8) Treat with Peroxide Block for 10 minutes. 
9) Wash in TBS buffer for 5 minutes with 2 changes. 
10) Treat with Power Block for 10 minutes. 
11) Drain the slides and cover with primary antibody (supplied from  
BIOGENEX) for 2 hours. 
12) Wash in TBS buffer for 5 minutes with 2 changes. 
13) Cover the slides with Super Enhancer for 30 minutes. 
14) Wash in TBS buffer for 5 minutes with 2 changes. 
15) Apply HRP polymer reagent and leave for 30 minutes. 
16) Wash in TBS buffer for 5 minutes with 2 changes. 
17) Treat with DAB Chromogen with Substrate buffer for 5 to 8 
minutes. Diamino benzidene gives a brown colour to the antigen 
antibody reaction site. This should be used with caution, because it is 
carcinogenic. 
18) Wash in TBS for 5 minutes with 2 changes. 
19) Wash the slides in tap water for 5 minutes. 
20) Counterstain with Mayer’s Hematoxylin for 1 minute. 
21) Wash in tap water for 5 minutes. 
22) Air dry and mount with DPX. 
 Tumour cells are scored positive if there is golden brown cytoplasmic 
staining in the neoplastic cells. 
INTERPRETATION: Bcl2 positivity will be indicated by cytoplasmic 
positivity in glandular and stromal cells. Placenta is used as a control for 
Bcl-2 cytoplasmic grading, in which the syncytiotrophoblast cells stain 
for grade 4 positivity
20
.   Ki67 positivity is indicated by nuclear positivity 
in glandular cells. The mean percentage of positive glandular cells for 
both Bcl-2 and Ki-67in the functional layer of endometrium will be 
determined by counting 1000 cells in 10 randomly selected high power 
fields. There is no standard grading system for the Bcl-2 antigen. This 
grading is done based on the journals
14,15,17,20,73
. 
Positivity for both Bcl-2 and Ki67 will be scored as 
 grade1 = <25% 
grade 2= 25-50% 
grade 3= 50-75% 
grade4= 75-100% 
 Immunostaining intensity will be scored as 
 grade1= mild 
grade2= moderate 
grade3= strong 
grade4= very strong     
                                                        
Weighted score = positivity * intensity.  
Bcl-2 stains uniformly all glandular epithelial cells so number of cells 
showing positivity is always kept as grade 4. Ki67 only cells of very 
strong intensity are counted as positive so intensity is always kept grade  
4. So 4 is kept constant. Bcl-2 is graded, mainly based on the intensity 
and Ki67 is graded, mainly based on positivity and both are multiplied by 
4.  Thus maximum score is 16, and both Bcl-2 and Ki67 is given a score 
out of 16. 
 
  
TABLES AND CHARTS 
Table-1, Distribution of cases 
S.No Endometrial lesions Sample size Percentage 
1. Proliferative phase 12 24% 
2. Secretory phase 9 18% 
3. Disordered proliferative endometrium 6 12% 
4. Hyperplasia 10 20% 
5. EIN 3 6% 
6. Carcinoma 10 20% 
 Total 50 100% 
A total of 50 endometrial samples were studied for Bcl-2 and Ki67 
expression which included 24% of proliferative endometrium, 18% of 
secretory endometrium, 12% of disordered proliferative phase, 20% of 
hyperplasias, 6% of EIN and 20% of carcinoma endometrium. 
 Chart-1 
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Table-2. Expression of Bcl-2 in various endometrial lesions. 
S.NO Endometrium 
lesions 
Sample 
size 
negative Score 
4 
score 
8 
Score 
12 
Score 
16 
mean 
score 
1. Proliferative 
phase 
12 - 3 4 4 1 9 
2. Secretory  
phase 
9 6 2 1 - - 1.77 
3. Disordered 
proliferative 
phase 
6 1 2 2 1 - 6 
4. Hyperplasia 10 2 3 2 1 2 7.2 
5. EIN 3 - - 2 1 - 9.3 
6. Carcinoma 10 5 1 - 2 2 6 
 Total     50       
 
Bcl-2 showed maximum expression in proliferative phase and EIN, equal 
expression in carcinoma and disordered proliferative phase. Hyperplasia 
showed slightly higher expression than disordered proliferative phase. 
Secretory phase shows decreased expression compared to all lesions. 
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Table-3, Expression of Ki67 in various endometrial lesions 
S. 
No 
 
Endometrial  
lesions 
Sample  
size 
negative Score 
4 
Score 
8 
Score 
12 
Score 
16 
Mean 
score 
1. 
Proliferative  
phase 
12 
 
4 7 1 - - 3 
2. 
Secretory  
phase 
9 
 
7 2 - - - 0.88 
3. 
Disordered 
proliferative  
phase 
6 3 
3 
 
- - - 2 
4. Hyperplasia 
10 
 
5 3 1 - 1 3.6 
5. EIN 
3 
 
1 
 
- - - 2 10.6 
6. Carcinoma 10 5 1 2 1 1 4.8 
 Total 50       
 
Ki-67 showed maximum expression in EIN followed by carcinoma. 
Hyperplasia and proliferative phase showed almost equal expression. The 
Ki67 expression was reduced in disordered proliferative endometrium 
and markedly decreased in the secretory phase.  
 
 
 
 
 
 
 
 
  
 
Chart-3, Expression of Ki67 in various endometrial lesions 
 
 
PP- Proliferative phase. 
SP-  Secretory phase 
DPP- disordered proliferative phase. 
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Table-4, Comparison of Bcl -2 and Ki-67 in various 
endometrial lesions 
 
S.NO Endometrial lesions Bcl-2 mean score Ki67 mean score 
1. 
 
Proliferative phase 9 3 
2. Secretory phase 1.77 0.88 
3. Disordered proliferative 
phase. 
6 2 
4. Hyperplasia 7.2 
 
3.6 
5. EIN 9.3 
 
10.6 
6. Carcinoma 6 
 
4.8 
 
 
Both Bcl-2 and Ki67 showed highest expression in EIN and lowest 
expression in secretory phase. Bcl-2 showed higher expression in 
proliferative phase, disordered proliferative endometrium and hyperplasia  
than Ki-67. 
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 Table-5, Expression of Bcl-2 and Ki67 in cyclical endometrium 
S.No Endometrial phase  Sample 
size 
Bcl-2 mean 
score 
Ki67 mean 
score 
1. Proliferative phase 12 9 3 
2. Early Secretory phase 3 5.33 2.66 
3. Mid secretory phase 3 0 0 
4.  Late secretory phase 3 0 0 
 
Both Bcl-2 and Ki67 expression was high in the proliferative phase 
and showed decreased expression in the early secretory phase. In the mid 
and late secretory phase both markers showed immunonegativity. 
 
Chart-5,Expression of Bcl-2 and Ki67 in cyclical endometrium 
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 Table-6, Expression of Bcl-2 and Ki67 in disordered proliferative 
phase and hyperplasia 
S. No Type of endometrium 
Sample  
size 
Bcl-2 mean 
score 
Ki67 mean 
score 
1. Disordered proliferative phase 6 6 2 
2. Simple hyperplasia without atypia 5 7.2 2.4 
3. Simple hyperplasia with atypia - - - 
4. Complex hyperplasia without atypia 3 6.66 2.66 
5. Complex hyperplasia with atypia 2 8 8 
 
Out of the 6 cases of disordered proliferative endometrium Bcl-2 
showed positivity in 83.3% of the cases and Ki67 showed positivity in 
50% of the cases. Both Bcl-2 and Ki67 showed highest score in complex 
hyperplasia with atypia and almost equal expression in simple and 
complex hyperplasia. 
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 Table-7, Expression of Bcl-2 and Ki67 in EIN and Carcinoma 
S. NO Endometrial lesions 
Sample 
size 
Bcl-2 Ki67 
1. EIN 3 9.3 10.6 
2. Endometrial adenocarcinoma grade -1 6 7.33 2 
3. Endometrial adenocarcinoma grade-2 1 16 16 
4. Endometrial adenocarcinoma grade-3 1 0 12 
5. Serous intraepithelial carcinoma 1 0 0 
6. Serous adenocarcinoma 1 0 8 
 
3 cases of EIN was studied and both Bcl-2 and Ki-67 showed maximal 
expression in EIN compared to all endometrial lesions. Bcl-2 expression 
was maximum in grade1 and grade 2 tumours and was immunonegative 
for grade 3 carcinoma, serous EIC and serous adenocarcinoma. Ki67 
expression showed maximum expression in grade 2 and grade 3 tumours 
and its expression decreased in grade 1 endometrioid adenocarcinoma   
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 Table-8,Expression of Ki67 index in  Carcinoma 
S. NO Endometrial lesions Sample  
size 
Ki67 mean 
 index 
1. Endometrial adenocarcinoma grade -1 6 15% 
2. Endometrial adenocarcinoma grade-2 1 78% 
3. Endometrial adenocarcinoma grade-3 1 60% 
4. Serous intraepithelial carcinoma 1 0 
5. Serous adenocarcinoma 1 42% 
 
Ki67 expression showed maximum expression in grade 2 and grade 3 
tumours and its expression decreased in grade 1 endometrioid 
adenocarcinoma. 
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Fig-1, Proliferative phase showing cytoplasmic positivity of Bcl
Fig-2, Proliferative phase showing cytoplasmic positivity of Bcl
grade-1, 10X 
 
 
 
grade-2, 10X. 
 
 
-2 
 
-2         
Fig-3, Proliferative phase showing grade 3 cytoplasmic positivity of    
Fig-4,10X, Proliferative phase showing nuclear positivity of Ki67
Bcl-2,10X 
 
 
 
 
 
 
 
 Fig-5, H&E, Early secretory phase showing subnuclear vacuoles 
10X 
 
 
 
Fig-6, 10X view, Secretory phase showing nuclear positivity of Ki67 
 
 
 Fig-7,10X view, H&E, Simple hyperplasia showing cystically dilated 
glands. 
 
 
 
Fig-8,10X, Simple hyperplasia showing grade 4 ,cytoplasmic         
positivity of Bcl-2 
 
 
 Fig-9, 10X , Simple hyperplasia showing nuclear positivity of Ki67. 
 
 
 
 
Fig-10, 10X, H&E complex hyperplasia showing complex branching 
glands 
 
 
 Fig-11, Complex hyperplasia with atypia showing nuclear        
positivityof Ki67, 10X 
 
 
 
Fig-12, EIN showing focal glandular crowding with little         
intervening stroma, 10X. 
 
 
Fig-13, EIN showing grade 3, cytoplasmic positivity of Bcl
Fig-14, EIN showing nuclear positivity of Ki67, 
 
 
 
 
 
 
 
 
-2, 10X 
 
10X. 
  
 
 
 
 
 
 
 
 
 
 
Fig-15, Gross picture of endometrial carcinoma of uterus showing a 
proliferative growth filling the entire endometrial cavity and extending up 
to the serosa. 
 
 
 
 
 
 
 
 
 
 
Fig-16, Well differentiated endometrioid adenocarcinoma showing 
to back arrangement of glands with nuclear atypia, 10X.
Fig-17, Well differentiated endometrioid adenocarcinoma showing    
grade 4 cytoplasmic positivity of Bcl
 
 
-2, 10X
 
 
 
 
back 
 
 
 
 Fig-18, Moderately differentiated adenocarcinoma showing high degree 
of nuclear atypia. 10X 
 
 
 
 
Fig-19, Moderately differentiated adenocarcinoma showing grade 4 
cytoplasmic positivity of Bcl-2, 10X 
 
Fig-20, Poorly differentiated carcinoma showing sheet of undifferentiated 
Fig-21, Poorly differentiated carc
cells, 10X view 
 
 
inoma showing nuclear positivity of 
Ki67, 10X view 
 
 
 
 Fig-22, Serous adenocarcinoma of the endometrium showing papillary 
structures with cells showing high degree nuclear pleomorphism, 10X 
 
 
 
Fig-23, 40X, Serous adenocarcinoma, nucleus showing macronucleoli 
and apoptotic bodies 
 Fig 24, 40X, Serous adenocarcinoma showing nuclear positivity of Ki67 
 
 
 
Fig-25, 10X , Serous intraepithelial carcinoma showing papillary 
structures resistricted to the endometrium and does not cross the 
endometrial myometrial junction. 
 
 
DISCUSSION 
A total of 50 endometrial samples were studied for Bcl-2 and Ki67 
expression which included 24% of proliferative endometrium, 18% of 
secretory endometrium, 12% of disordered proliferative phase, 20% of 
hyperplasias, 6% of EIN and 20% of carcinoma endometrium. 
Bcl-2 expression based on positivity alone in descending order of 
frequency, 100% of positivity was observed for proliferative 
endometrium and endometrial intraepithelial neoplasia, 83.3% of 
positivity for disordered proliferative endometrium, 80% of positivity 
was observed in hyperplasia whereas endometrial carcinoma was only 
50% positive and secretory endometrium showed positivity of only 
33.3%. 
Ki67 expression based on positivity in descending order of 
frequency showed 66.6% positivity in both proliferative and endometrial 
intraepithelial neoplasia . 50% of positivity was expressed by disordered 
proliferative endometrium, hyperplasia and carcinoma, 22.2% was 
observed in secretory phase.  
My discussion is based on the score which includes both positivity 
and intensity as mentioned earlier. 
In cyclical endometrium, 12 cases of proliferative endometrium 
and 9 cases of secretory endometrium out of which 3 cases each in early, 
mid and late secretory phases were studied. Mean Bcl-2 score was 9 in 
proliferative phase 1.77 in secretory phase whereas mean Ki67 score was 
3 in proliferative phase and 0.88 in secretory phase. Thus both Bcl-2 and 
Ki67 expression was high in the proliferative phase and showed 
decreased expression in the early secretory phase. In the mid and late 
secretory phase both markers showed immunonegativity. 
According to study done by Mertens H J MM
9
 et al in 30 endometrial 
samples of ovulatory cyclical endometrium, Bcl2 expression was high in the 
proliferative phase and decreased significantly in the secretory phase, 
especially in the glandular epithelial cells. Ki67 also showed the same cyclical 
pattern with a later onset.  
According to a study done by T. E. Vaskivuo
10
 et al using 39 
endometrial samples the results were Bcl-2 expression increased in the 
proliferative phase and decreased in the secretory phase being very low or 
absent in the secretory and menstrual phases. Ki-67 was detected 
predominantly in the proliferative phase.  
A study done by X J Tao
11
 et al states that Bcl-2 immunoreactivity 
was maximal during the proliferative phase and decreased in the 
secretory phase.  
 
A study done by A. Gompel
12
 et al in 49 endometrial samples of 
which 26 were proliferative endometrium and 23 were secretory 
endometrium and the results is that Bcl2 staining peaked at the 
proliferative phase and disappeared with the onset of secretory phase.  
So my study results were consistent with that of these previous 
studies. 
Comparison was done between Bcl-2 and Ki67 using paired 
sample t- test. The results were p<0.01 for proliferative phase, which was 
significant at 1% level. This means that anti-apoptotic activity and the 
mitotic activity are high in the proliferative phase. 
 The secretory phase showed p>0.05, which means not significant. 
The secretory endometrium which prepares itself for endometrial 
breakdown is characterized by increased apoptotic and decreased mitotic 
activity. 
Out of the 6 cases of disordered proliferative endometrium Bcl-2 
showed positivity in 83.3% of the cases and Ki-67 showed positivity in 
50% of the cases. 
Comparison of Bcl-2 and Ki67 in disordered proliferative phase 
using paired sample t- test gave the results p<0.05 which was significant. 
There was increased proliferative activity similar to the normal 
proliferative endometrium.  
Of the total 10 cases of hyperplasias, 5 cases were simple 
hyperplasia, 3 were complex hyperplasia and 2 cases were complex 
hyperplasia with atypia. Of this Bcl-2 positivity was observed in 80% of 
the cases whereas Ki67 showed a positivity of only 50%. Both Bcl-2 and 
Ki67 showed highest score in complex hyperplasia with atypia and 
almost equal expression in simple and complex hyperplasia. 
Theodore H. Niemann
25
 et al states that Bcl-2 protein expression 
was 100% in complex hyperplasia, 25% in complex atypical hyperplasia 
and 34% in cases of carcinoma. Complex atypical hyperplasia and 
carcinoma showed focal staining which was less in intensity than the 
normal proliferative endometrium. 
    Robert
24
 et al states that, the Ki67 mean index of 68 endometrial 
samples in descending order of frequency were as follows. Highest 
expression was observed in proliferative phase followed by complex 
hyperplasia, atypical complex hyperplasia, and simple hyperplasia. The 
least score was observed in atrophic endometrium. 
Morsi, Hassan
23
 et el states that , 107 endometrial samples studied 
which included eighteen cases of proliferative endometrium,  nineteen 
cases of secretory endometrium, fifteen cases of postmenopausal 
endometrium , six cases of disordered proliferative endometrium, twelve 
cases of simple hyperplasia, eight cases of  complex hyperplasia, and 
twenty nine cases of endometrial adenocarcinoma. And the results were 
high expression of Bcl-2 and Ki-67 was observed in proliferative 
endometrium, post menopausal endometrium and complex hyperplasia. 
Secretory endometrium showed decreased expression of both the 
markers. In endometrial carcinoma Ki67 showed increased expression as 
the grade progressed, where as Bcl-2 reacted only weakly and only in 
grade 1 cancer. 
Olga B Ioffe
27
 et al states that cytoplasmic Bcl-2 expression 
increased from benign proliferative endometrium to simple hyperplasia 
and decreased in complex hyperplasia and carcinomas. Ki67 index was 
increased in proliferative endometrium and carcinoma and was decreased 
in simple and complex hyperplasia.  
  In my study both Bcl-2 and Ki-67 expressed highest score in 
complex hyperplasia with atypia, followed by simple hyperplasia and 
complex hyperplasia without atypia.  
Correlating values of Bcl-2 and Ki-67 for the 10 cases of 
hyperplasia using t-test showed p>0.05, not significant. 
 
3 cases of EIN was studied and both Bcl-2 and Ki-67 showed 
maximal expression compared to all endometrial lesions. Although the 
sample size is low, all the 3 cases of EIN showed 100% positivity for 
both Bcl-2 and Ki-67. This indicates that both anti- apoptotic activity and 
proliferative activity are high in the EIN, which is monoclonal 
proliferation of neoplastic cells. This denotes increased propensity for the 
EIN lesions to evolve in to cancer. 
Mahrosa M.M.Khedr
30
 et al states that normal proliferative 
endometrium expressed high levels of both Ki-67 and Bcl-2. Ki-67 
positivity sequentially increased from endometrial hyperplasia through 
EIN to endometrial carcinoma. In contrast Bcl-2 positivity was decreased 
significantly in cases of endometrial carcinoma mainly the high grade.  
Correlating values of Bcl-2 and Ki-67 for the 3 cases of EIN using 
t-test showed p>0.05, not significant. 
In case of carcinoma total of 10 cases were studied, out of that 6 
cases were well differentiated carcinoma, 1 case was grade-2 and 1 case 
was grade-3, each 1 case of serous endometrial intraepithelial carcinoma 
and 1 case of serous adenocarcinoma. 
Bcl-2 expression was maximum in grade-1 and grade-2 tumours 
and was immunonegative for grade-3 carcinoma, serous EIC and serous 
adenocarcinoma. Ki-67 mean index was 15% for grade -1 carcinoma and 
it was 78% for grade-2 carcinoma, 60% for grade-3 carcinoma, 42% in 
serous adenocarcinoma and was immunonegative for serous endometrial 
intraepithelial carcinoma.  Thus Ki67 index increases with the grade of 
the tumour and also correlates with expression of serous adenocarcinoma 
which is around 40% according to literature
4
. 
Bozdogen
69
 et al states that Bcl-2 expression was maximum in 
hyperplasia compared to carcinoma. In normal endometrium Bcl-2 
staining showed increased intensity in the proliferative phase, but 
decreased in the early and mid secretory phase and reappeared in the late 
secretory phase. 
        Dahmoun M
70
. et al states that Bcl-2 showed no correlation to 
apoptotic index. The Ki67 index was higher and more heterogeneous in 
grade-2 and grade-3 tumours than grade-1 tumour. 
         Halperin R
71
 et al states that the endometrioid adenocarcinoma 
grade-1 to grade-2 cases were characterized by increased 
immunoreactivity for Bcl-2, where as serous papillary endometrial 
adenocarcinoma and poorly differentiated adenocarcinoma also showed 
immunonegativity for Bcl-2.  
 
         Yamauchi
66
 et al states that expression of Bcl-2 progressively 
decreased from low grade to high grade carcinoma and Ki67 index 
increased from low grade to high grade carcinoma.  
          Kosmas
67
 et al states that Ki67 immunocytochemistry showed type-
II endometrioid adenocarcinoma showed higher expression than type-I 
carcinoma. High grade tumours showed increased Ki67 expression than 
low grade tumours. Ki67 index was higher in proliferative phase 
endometrium than that of grade-1 and type-I endometrioid 
adenocarcinoma. In secretory phase the expression was markedly 
diminished. 
           Wenxin Zheng 
72
 et al states that Bcl-2 staining intensity was 
higher in the proliferative endometrium and hyperplasia, which 
diminished in endometrioid adenocarcinoma and serous papillary 
adenocarcinoma. 
             In my study the expression of Bcl-2 is maximum in grade-1 and 
grade-2 tumors and is immunonegative in poorly differentiated carcinoma 
and serous adenocarcinoma. This loss of Bcl-2 expression is associated 
with increased apoptotic activity. Serous adenocarcinoma shows 
increased apoptotic bodies and this correlates with the immunonegativity 
for Bcl-2. Thus my study correlates with the study done by, Halperin and 
Yamauchi et al. 
             Ki67 expression showed maximum expression in grade-2 and 
grade-3 tumours and its expression decreased in grade-1 endometrioid 
adenocarcinoma. This denotes that mitotic activity progressively 
increases with grade of the tumor.  It expression is increased in high 
grade serous adenocarcinoma. Thus my result correlates with most of the 
above studies.  
              I observed that Bcl-2 expression decreases with higher tumour 
grade whereas Ki-67 index increases. This indicates increased apoptotic 
and mitotic activity with higher grade carcinomas. 
               Comparison of Bcl-2 and Ki67 in carcinoma using t-test showed 
p>0.05 i.e not significant and they show inverse relationship. 
              There are few drawbacks in this study which are as follows. 
Immunohistochemistry is a highly meticulous procedure. The antigen 
retrieval which is an important step is influenced by various factors such 
as use of old blocks, tissue fixed in formalin for long period, inadequate 
time of heating, pH of the buffer etc. Further if sample size is increased 
better results can be obtained. Since this immunohistochemistry is an 
expensive procedure , large sample could not be studied. 
 
 
 
 
 CONCLUSION 
 
         Of the 50 cases studied, in cyclical endometrium, Bcl-2 expression 
was maximum in the proliferative phase and decreased in the early 
secretory phase and was immunonegative in the mid and late secretory 
phases. Ki67 expression in cyclical endometrium was maximum in the 
proliferative phase and decreased in early secretory phase and was 
immuno negative in the mid and late secretory phase. This denotes that 
the proliferative endometrium has increased proliferative activity and 
decreased apoptotic activity.  Comparison of Bcl-2 and Ki-67 values in 
proliferative phase shows a positive correlation statistically. Thus the 
proliferative endometrium is characterized by decreased apoptotic and 
increased mitotic activity in response to estrogen. This proves the 
association of hyper estrogenic states in causing increased proliferation 
leading to neoplasm.    
           In secretory phase as the endometrium prepares itself for shedding 
there is increased apoptosis which results in loss of Bcl-2 expression. 
Mitotic activity is also significantly reduced resulting in decreased Ki67 
expression.  
          Disordered proliferative endometrium and hyperplasia both of 
which are associated with hormonal imbalance show equal and higher 
expression of Bcl-2 indicating the decreased apoptotic activity in these 
proliferative states. Coming to mitotic index, again both of these show 
almost equal expression, but are lesser than Bcl-2. This denotes that these 
conditions are associated with an imbalance in both apoptotic and mitotic 
activity.  
                 Endometrial intraepithelial neoplasia showed 100% positivity 
for both Bcl-2 and Ki-67 denoting the high mitotic activity and low 
apoptotic activity in this clonal neoplasm. This indicates the increased 
potential for these lesions to transform into frank malignancies.  
           Bcl-2 expression decreases with increasing grade of the tumour 
whereas Ki-67 index increases. This indicates increased apoptotic and 
mitotic activity with higher grade carcinoma and negative correlation of 
the Bcl-2 and Ki67 expression.  
 
  This negative correlation means the imbalance between the 
apoptotic and mitotic activity is responsible for the development of 
neoplastic conditions. The failure of apoptotic mechanism to remove the 
damaged and mutated cells combined with the proliferating ability of the 
neoplastic cells is responsible for the tumorigenesis.  
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PROFOMA 
Department of pathology  
Coimbatore medical college,  
Coimbatore. 
Patients name:_________________ 
Age/ Sex:_____________________ 
IP No: _______________________ 
Occupation: ___________________ 
Income: ______________________ 
Address: ______________________ 
HPE NO: _____________________ 
PRESENTING ILLNESS 
History of presenting illness: __________ 
History of bleeding: Amount- Heavy/ moderate / scant/ variable 
                                  Duration____________ 
History of dysmenorrhoea: ___________ 
History of white discharge: ______________ 
OBSTETRIC HISTORY 
Married since ______   years. 
Para:  ______________       History of abortions: ______________ 
Last child birth: ___________ 
Sterilisation history: ____________ 
MENSTRUAL HISTORY 
Age of menarche: ___________ 
Menstrual cycles: regular/ irregular,   Duration: 
Amount of bleeding: Heavy/ moderate / scant/ variable 
PERSONAL HISTORY 
Diet history: _____________ 
Appetite: ________________ 
Bladder and Bowel habits: ___________ 
PAST HISTORY 
History of diabetes/  hypertension/ tuberculosis/endocrine disorders/ 
bleeding disorders. 
History of any other major illness: ____________ 
History of drug intake: ______________ 
GENERAL EXAMINATION 
Built and nourishment: ________________ 
Pallor /icterus/ lymphadenopathy/ pedal edema  
Pulse:                          
Blood pressure: 
SYSTEMIC EXAMINATION 
Cardiovascular system: 
Respiratory system: 
Per abdomen: Liver- palpable/ normal 
                        Spleen- palpable/ normal 
Central nervous system: 
LOCAL EXAMINATION 
Speculum examination:  
Vulva: Healthy / unhealthy 
Vagina: presence of vaginitis/ normal 
Cervix : healthy/ unhealthy  
Vaginal examination: 
Cervix: Direction: 
              Consistency: 
              Bleeds on touch:  yes/ no 
              Cervical erosion: present/ absent 
Uterus: Anteverted / Retroverted 
              Normal/ bulky/ small 
               Mobile/ fixed. 
LABORATORY INVESTIGATIONS 
1. URINE: Albumin 
                    Sugar 
                    Microscopy 
2. HEMATOLOGY 
Hemoglobin: _______________gm% 
RBC count: _________________millions/cu mm 
Total WBC count: ___________/ cu mm 
PCV: __________% 
MCV: __________fl 
MCH: ___________ pg 
MCHC: __________gm% 
Differential count: 
Platelet count: ______________/ cu mm 
 E.S.R: _____________ mm/hr 
Blood group and Rh type: 
Bleeding time: _____________ Clotting time: 
Peripheral smear : 
3. BIOCHEMICAL TEST 
Blood glucose: __________mg/dl 
Blood urea: _____________mg/ dl 
Serum creatinine: ___________mg/dl 
4. RADIOLOGICAL INVESTIGATION 
Ultrasound findings: 
Others: 
5. BIOPSY AND HYSTRECTOMY SPECIMENS. 
Biopsy 
Gross appearance: 
Microscopic features: 
Hysterectomy specimens 
Gross appearance:  Size of the specimen 
                                Size of the growth, 
                                Proliferative/ Irregular/ polypoidal/ infiltrative growth 
                                Myometrial involvement, Serosal extension 
                                Cervical involvement, Isthmic involvement,  
                                Parametrial involvement,  Vaginal cuff involvement, 
                                Lymphnode status 
MASTER CHART 
S.No HPE No IP No Age 
Clinical 
Diagnosis 
Histo 
pathological 
BCL -2  
Score - 
16 
KI 67 
Total 
Score 16 
1 G 1848/11 57731 56 DUB PP 8 4 
2 G 13351/11 24990 42 DUB PP 8 4 
3 G 1888/11 61525 40 DUB PP 8 4 
4 E 427/11 44617 45 
Fibroid 
Uterus PP 4 0 
5 G 1357/11 41674 40 DUB PP 16 4 
6 G 1184/11 32356 44 
Fibroid 
Uterus PP 12 0 
7 G 44A/12 97287 45 
Fibroid 
Uterus PP 12 8 
8 G 203/12 75593 33 DUB PP 4 0 
9 G265/12 30401 45 
Fibroid 
Uterus PP 12 4 
10 G910/12 37267 40 DUB PP 8 4 
11 G911/12 37739 29 
Fibroid 
Uterus PP 4 4 
12 G1393/11 41447 38 
Fibroid 
Uterus PP 12 0 
13 G1436/11 56747 54 
Fibroid 
Uterus ESP 8 4 
14 G881/12 37147 32 DUB ESP 4 0 
15 G943/12 36667 35 DUB ESP 4 4 
16 G888/12 35878 52 
Fibroid 
Uterus MSP 0 0 
17 G938/12 37749 38 
Fibroid 
Uterus MSP 0 0 
18 G953/12 46080 36 DUB MSP 0 0 
19 G1767/11 48864 40 
Fibroid 
Uterus LSP 0 0 
20 G1877/11 63431 44 DUB LSP 0 0 
21 E15/12 385 47 
Fibroid 
Uterus LSP 0 0 
22 G2090A/11 69519 55 DUB DPP 12 4 
23 G171/12 62681 37 DUB DPP 4 4 
24 G879/12 33079 21 DUB DPP 4 0 
25 G887/12 31354 43 DUB DPP 8 4 
26 G900/12 36596 21 DUB DPP 8 0 
27 G299/12 50637 40 DUB DPP 0 0 
28 G1470/11 45129 52 
Fibroid 
Uterus SH 16 8 
29 G1747/11 57517 40 
Fibroid 
Uterus SH 0 0 
30 G971/11 28457 35 DUB SH 8 0 
31 G441/11 79604 41 
Fibroid 
Uterus SH 4 4 
32 E50/12 10202 35 
Fibroid 
Uterus SH 8 0 
33 G1926/11 65321 40 DUB CH 16 4 
34 G1193/11 38678 32 DUB CHWA 4 0 
35 E728/11 95831 43 DUB CH 4 4 
36 G175/12 6325 42 DUB CH 0 0 
37 G1608/11 51478 57 
Postmonopa
usal 
Bleeding CHWA 12 16 
38 G1594/11 47678 50 
Postmonopa
usal 
Bleeding EIN 8 16 
39 P472/11 80301 56 
Postmonopa
usalBleeding EIN 12 16 
40 E728/11 9583 43 
Postmonopa
usal 
Bleeding EIN 8 0 
41 G1373/11 44625 55 
Postmonopa
usal 
Bleeding EAG-1 16 8 
42 G186/11 5173 65 
Postmonopa
usal 
Bleeding EAG-1 12 4 
43 G426/11 4784 47 
Cainomal  
endometaum EAG-1 12 0 
44 G65/12 4651 53 
Postmonopa
usal 
Bleeding EAG-1 0 0 
45 G177/12 71940 65 
Postmonopa
usal 
Bleeding EAG-1 0 0 
46 G890/12 32295 59 
Postmonopa
usal 
Bleeding EAG-1 4 0 
47 G1291/11 41686 50 
Postmonopa
usal 
Bleeding EAG-2 16 16 
48 G1374/11 44198 59 
Postmonopa
usal 
Bleeding EAG-3 0 12 
49 G1051/11 32071 65 
Postmonopa
usal 
Bleeding SA 0 8 
50 G139/12 43001 61 
Postmonopa
usal 
Bleeding SIEC 0 0 
KEY TO MASTER CHART 
PP - Proliferative Phase 
ESP - Early Secretory Phase 
MSP - Mid Secretary Phase 
LSP - Late Secretary Phase 
DPP - Disordered Proliferative Phase 
SH - Simple Hyperplasia  
CH - Complex Hyperplasia 
CHWA - Complex Hyperplasia Without Atypia 
EIN - Endometrial Intraepithelial Neoplasia  
EAG 1 - Endometrial Adenocarcinoma grade-1 
EAG2 - Endometrial Adenocarcinoma grade-2 
EAG 3 - Endometrial Adenocarcinoma grade-3 
SA - Serous Adenocarcinoma  
SIEC - Serous Intraepithelial Carcinoma  
DUB - Dysfunctional Uterine Bleeding 
 
 
 
 
 
 
 
EXPRESSION OF Bcl-2 AND Ki-67 IN ENDOMETRIAL 
LESIONS 
 
ABSTRACT 
The human endometrium shows dynamic morphological changes such as 
proliferation with high mitotic activity and secretion followed by 
shedding of the cells to complete the menstrual cycle. This proliferative 
activity is kept under check by balanced apoptotic activity. 
Aim and objective : Aim  of this thesis is to study the apoptotic and 
mitotic activity of the human endometrium by immunohistochemistry 
using the markers Bcl-2 an anti- apoptotic gene and Ki-67 a recognised 
indicator of mitotic activity. This is studied in the cyclical endometrium 
and various endometrial lesions such as hyperplasia, premalignant 
conditions and carcinoma. 
Materials and methods:  A total of 50 endometrial samples were studied 
which included dilation and curettage specimens and hysterectomy 
specimens received by the department of pathology, Coimbatore medical 
college, Coimbatore.  
Results:  A total 50 endometrial samples  were studied which incuded 12  
proliferative endometrium, 9 secretory endometrium, 6 cases of 
disordered proliferative endometrium , 10 cases of hyperplasia, 3 cases of 
EIN and 10 cases of carcinoma. The results are Bcl-2 expression was 
increased in the proliferative phase and decreased in the secretory phase. 
Disordered proliferative phase , hyperplasia and carcinoma showed 
almost equal expression . EIN showed maximum expression compared to 
all endometrial lesions. Similarly Ki-67 showed higher expression in the 
proliferative phase and decreased in the secretory phase. Expression of 
Ki-67 in other lesions in descending order of frequency are EIN, 
carcinoma, hyperplasia followed by disordered proliferative 
endometrium. Comparison of Bcl-2 and Ki-67 in all endometrial lesions 
showed positive correlation in the proliferative phase and disordered 
proliferative endometrium, which means that there is decrease in 
apoptosis and increased mitotic activity in these states. In carcinoma there 
was negative correlation, where the expression of Bcl-2 decreased with 
the increase in grade of the tumour and Ki-67 expression increases with 
the grade of the tumour. 
Conclusion:   The imbalance between the apoptotic and mitotic activity 
is responsible for the development of neoplastic conditions. The failure of 
apoptotic mechanism to remove the damaged and mutated cells combined 
with the proliferating ability of the neoplastic cells is responsible for the 
tumorigenesis. 
 
 
 
 
